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FLEXIBLE MODELS OF TIME-VARYING EXPOSURES
With the availability of electronic medical records, medication dispensing data offers
an unprecedented opportunity for researchers to explore complex relationships among long-
term medication use, disease progression and potential side-effects in large patient popula-
tions. However, these data also pose challenges to existing statistical models because both
medication exposure status and its intensity vary over time. This dissertation focused on
flexible models to investigate the association between time-varying exposures and different
types of outcomes. First, a penalized functional regression model was developed to esti-
mate the effect of time-varying exposures on multivariate longitudinal outcomes. Second,
for survival outcomes, a regression spline based model was proposed in the Cox proportional
hazards (PH) framework to compare disease risk among different types of time-varying ex-
posures. Finally, a penalized spline based Cox PH model with functional interaction terms
was developed to estimate interaction effect between multiple medication classes. Data from
a primary care patient cohort are used to illustrate the proposed approaches in determining
the association between antidepressant use and various outcomes.
Sujuan Gao, Ph.D., Co-Chair
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Chapter 1
Introduction
An electronic medical record (EMR) is a systematic collection of electronic health informa-
tion about an individual patient. It is a record in digital format that is theoretically capable
of being shared across different health care settings, including enormous quantities of clinical
data such as medical diagnosis, laboratory testing and medication dispensing information.
They have been increasingly used in many health systems around the country, which offers
an unprecedented research opportunity for monitoring disease development, progression and
treatment. In particular, medication dispensing data allow researchers to explore complex
relationships among long-term medication use, disease progression and potential side-effects
in large patient populations. However, these data also pose challenges to existing statistical
models because both medication exposure status and its intensity vary over time, known
as time-varying exposure in many studies. Many medical journals published studies used
summarized exposure measures such as current dose (Smitten et al., 2008), average daily
dose (Wolfe et al., 2006), or a simple sum of past exposures (Stranges et al., 2006). Few
studies on long-term medication effects fully utilize the medication information contained
in EMR data.
We have developed several novel approaches for assessing the effect of time-varying expo-
sures on longitudinal and survival outcomes. First, a penalized functional regression model
was developed to estimate the effect of time-varying exposure on multivariate longitudinal
outcomes. Second, for survival outcomes, a regression spline based model was proposed in
the Cox proportional hazards (PH) framework to compare disease risk among different types
of time-varying exposures. Finally, a penalized spline based Cox PH model with functional
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interaction terms was developed to estimate potential interaction effect between multiple
medication classes.
1.1 Time-varying exposure and multivariate longitudinal outcomes
To accommodate time-varying exposures statistically, Breslow et al. (1983) and Thomas
(1988) were among the first ones to propose a weighted cumulative exposure (WCE) mea-
sure with predetermined weights to summarize time-varying exposures. Later on, various
approaches have also been proposed using nonparametric methods to estimate the weight
function in generalized linear models (Berhane et al., 2008; Hauptmann et al., 2000) and
Cox proportional hazards models (Gasparrini, 2013; Sylvestre and Abrahamowicz, 2009).
In the meanwhile, functional regression models have been developed for time-varying co-
variates where the functional coefficients can be interpreted as the weight functions for
time-varying exposures. Zhang et al. (2007) evaluated the effect of time-varying follicle
simulating hormone during a menstrual cycle on total hip bone mineral density and used a
two-stage functional mixed model with periodic cubic smoothing splines to estimate the co-
efficient function. Schipper et al. (2008) proposed a generalized monotonic functional mixed
model (GMFMM) with regression splines to relate a functional measure of radiation dose
to a normal tissue complication outcome. A Bayesian GMFMM was also proposed for a
modified weight function (Schipper et al., 2007). Bhadra et al. (2012) presented a Bayesian
semi-parametric approach for time-varying exposure on a binary outcome in a case-control
study. For time-varying exposure and a single longitudinal outcome, Goldsmith et al. (2012)
developed a penalized functional regression model and compared a likelihood based method
and a Bayesian method for model estimation and inference.
In modeling medication effects, it is of scientific interest to determine the effect of long-
term medication use on a number of correlated longitudinal outcomes such as repeated
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systolic and diastolic blood pressure measures. In such situations, separate modeling of
systolic and diastolic outcomes may not be appropriate, as the two outcomes are biologically
correlated and mutually influential (Guo and Carlin, 2004; Liu et al., 2012). However, few
studies discussed the development of a multivariate longitudinal functional regression model
to estimate the exposure effects while controlling for the interdependency across correlated
outcomes.
In Chapter 2, we propose a multivariate semiparametric model on longitudinally mea-
sured outcomes with constrained coefficient functions for time-varying exposures.. In par-
ticular, we use penalized splines to flexibly estimate the coefficient functions and shared
random effects to model the correlations among the multivariate longitudinal outcomes.
We show that the proposed model has a mixed effect model representation so that the
model estimation and inferences can be achieved using standard statistical softwares.
1.2 Flexible models for comparing cumulative effects of time-varying expo-
sures
Many extensions have been made in defining weighted cumulative exposure recently. For
example, Berhane et al. (2008) proposed a tensor product spline model to jointly model age,
latency and exposure response effects for protracted time-dependent occupational exposure
histories in the Colorado plateau uranium miners cohort. Gasparrini (2013) noted out that
equivalent approaches were previously established in time series analysis. Analogous to the
weight function, the definition of a distributed lag function was introduced in distributed
lag models (DLMs) and distributed lag nonlinear models (DLNMs) in time series analysis.
Another existing problem that has not been addressed thus far is that in clinical practice
patients often receive different types of medications intended for the same medical condition
and it is of interest to compare the effects of these medication exposures on relevant health
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outcomes. However, little work has been done in comparing the effects of multiple medi-
cation exposures over an extended period using time to event outcomes. In Chapter 3, we
extend the regression spline-based method in Sylvestre and Abrahamowicz (2009) to model
WCE in multiple exposures settings where the weight functions for each exposure type can
be estimated, where a direct comparison between multiple exposures can be considered in
this unified modeling framework.
1.3 A penalized Cox proportional hazards model with time-varying exposures
and interaction term
One limitation of the methodology discussed in Chapter 3 is that we did not consider
patients who were on multiple types of medication simultaneously intended for the same
medical condition, which is quite common in clinical practice. Generally, patients take
multiple drugs during their follow-up periods. In clinical practice, it is usual for patients to
receive different types of medications intended for the same medical condition. For example,
depressed patients may switch from one type of antidepressants to another if the treatment
fails to show satisfactory efficacy. Patients with hypertension may take more than one
class of antihypertensive medications at the same time. Therefore, it is of interest to assess
the effects of multiple medications and their potential interaction effects on relevant health
outcomes.
Many functional regression models included only one functional covariate, such as in
Zhang et al. (2007), Schipper et al. (2008) and Bhadra et al. (2012). Goldsmith et al. (2012)
and Ferraty and Vieu (2009) included two or more functional covariates through additive
models. However, not much work has been done to study the interaction effect between
functional covariates. When the outcome of interest is a scalar, Fuchs et al. (2015) proposed
a penalized scalar-on-functions regression with interaction term, which extends the model
4
with only main effects in Wood (2011). To the best of our knowledge, the estimation of
interaction effects between functional covariates has not received much attention in survival
analysis setting.
In Chapter 4, we proposed a penalized Cox PH model with functional covariates and
their interaction. In particular, the coefficient functions for functional covariates have been
expanded using cubic B-spline basis for the main effects and tensor product splines for the
interaction effect. Penalized partial likelihood method was used to estimate the coefficient
functions and surfaces nonparametrically. Hypothesis tests of no interaction or no effect of
time-varying exposure were also discussed, based on Wald’s method.
5
Chapter 2
Time-varying exposure and multivariate longitudinal outcomes
2.1 Introduction
Electronic medical records (EMR) capture enormous quantities of clinical data including
medical diagnosis, laboratory testing, medication dispensing information and they have been
increasingly used in many health systems around the country. The availability of EMR
data offers an unprecedented research opportunity for monitoring disease development,
progression and treatment. In particular, medication dispensing data allow researchers
to explore complex relationships among long-term medication use, disease progression and
potential side-effects in large patient populations. Since many clinical trials for medication
approval were conducted in restrictive patient populations due to stringent exclusion criteria
with limited numbers of outcomes and over a relatively short period of time, the long-term
effect of medications on many health outcomes in the general patient population can be
better studied using EMR data.
Electronic medication dispensing data typically contain information on medication names,
dosage, and length for the dispensed medication. However, few studies on long-term medi-
cation effects fully utilize the information contained in EMR data. Many published studies
used summarized exposure measures such as current dose (Smitten et al., 2008), average
daily dose (Wolfe et al., 2006), or a simple sum of past exposures (Stranges et al., 2006).
Breslow et al. (1983) and Thomas (1988) were among the first ones to propose a weighted cu-
mulative exposure (WCE) measure with predetermined weights to summarize time-varying
exposures. Abrahamowicz et al. (2006) used a parametric WCE framework within the Cox’s
proportional hazards (PH) model to study the association between a time-varying exposure
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and event risk. Applications using WCE by simple parametric functions can also be found
in works by VACEK (1997) , Langholz et al. (1999), and Richardson (2009). Various ap-
proaches have also been proposed using nonparametric methods to estimate the weight
function in generalized linear models (Berhane et al., 2008; Hauptmann et al., 2000) and
Cox proportional hazards models (Gasparrini, 2013; Sylvestre and Abrahamowicz, 2009).
For scalar outcomes, functional regression models have been developed for time-varying
covariates where the functional coefficients can be interpreted as the weight functions for
time-varying exposures. Zhang et al. (2007) evaluated the effect of time-varying follicle
simulating hormone during a menstrual cycle on total hip bone mineral density and used
a two-stage functional mixed model with periodic cubic smoothing splines to estimate the
coefficient function. Schipper et al. (2008) proposed a generalized monotonic functional
mixed model (GMFMM) with regression splines to relate a functional measure of radiation
dose to a normal tissue complication outcome. A Bayesian GMFMM was also proposed for a
modified weight function (Schipper et al., 2007). Bhadra et al. (2012) presented a Bayesian
semi-parametric approach for time-varying exposure on a binary outcome in a case-control
studies. For time-varying exposure and a single longitudinal outcome, Goldsmith et al.
(2012) developed a penalized functional regression model and compared a likelihood based
method and a Bayesian method for model estimation and inference.
In modeling medication effects, it is often of interest to determine the effect of long-
term medication use on a number of correlated longitudinal outcomes such as repeated
systolic and diastolic blood pressure measures. In such situations, separate modeling of
systolic and diastolic outcomes may not be appropriate, as the two outcomes are biologically
correlated and mutually influential (Guo and Carlin, 2004; Liu et al., 2012). Therefore, a
multivariate longitudinal functional regression model needs to be developed in order to
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estimate the exposure effects more appropriately while controlling for the interdependency
across correlated outcomes.
In addition, when modeling the effect of exposure to medication or environmental tox-
ins, there is often prior evidence that exposures occurring long before an outcome may have
negligible influence, which suggests that the coefficient function should be bounded toward
zero at a distant boundary. By imposing such constraint would also avoid potential bound-
ary issues in estimating the coefficient functions using regression splines as encountered in
other studies (Sylvestre and Abrahamowicz, 2009). Schipper et al. (2008) considered similar
constraints on the coefficient function which force the functional value to be zero at zero
dose.
In this Chapter, we consider modeling multivariate longitudinal outcomes for the esti-
mation of time-varying exposures with constrained coefficient functions. In particular, we
use penalized splines to flexibly estimate the coefficient functions and shared random effects
to model the correlations among the multivariate longitudinal outcomes. We show that the
proposed model has a mixed effect model representation so that the model estimation and
inferences can be achieved using standard statistical softwares.
This Chapter is organized as follows. Section 2 describes data from a primary care
depression study as a motivating example for our methods. Section 3 introduces the con-
strained multivariate functional regression model and discusses parameter estimation and
point-wise confidence bands for the estimated coefficient functions. Section 4 presents the
results from a simulation study. In Section 5, we apply the proposed methods to the real
data and estimate the association between antidepressant use and longitudinal blood pres-
sure measures. We conclude the paper with a discussion in Section 6.
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2.2 A primary care depression screening cohort
A primary care patient cohort was assembled in 1991 as part of a depression screening study
in primary care clinics at Wishard Health Service. From 1991 to 1993, patients aged 60
years or older in Wishard Health Service were consented for depression screening during
their regular clinical visits to their primary care physicians. A total of 4,413 primary care
patients were initially contacted, of whom 115 refused; 57 were not eligible due to severe
cognitive impairment; 284 were not eligible because they were non-English speaking, in
prison, in a nursing home, or had a hearing impairment; 3,957 patients were enrolled in the
study. Details of the study have been published elsewhere (Callahan et al., 1994; McDonald
et al., 1999).
For enrolled patients, information including diagnosis of medical conditions, blood pres-
sure measures, laboratory test measures and medications order and dispensing was collected
by the Regenstrief Medical Record System (RMRS) (McDonald et al., 1999). The RMRS is
one of the first electronic medical record systems in the country and has been actively used
for research purposes. Originally implemented in 1973 and used continuously since then,
the RMRS serves as the day-to-day electronic medical record system at Wishard Hospital
and its community clinics - the third largest safety-net health care system in the U.S. Med-
ication dispensing information includes medication name, daily dose, and duration for each
dispensed medication. Our interest in this paper is to examine the association between a
class of antidepressants and longitudinally measured blood pressure levels.
Antidepressant is one of the most commonly prescribed medication groups in the United
States (Lindsley, 2012). An older class of antidepressants, tricyclic antidepressants(TCAs),
have been shown to have detrimental effect on cardiovascular function by inhibiting car-
diovascular Na(+), Ca(2+) and K(+) channels often leading to life-threatening arrhythmia
(Glassman, 1984; Jefferson, 1975). A newer class of antidepressants, selective serotonin
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reuptake inhibitors (SSRIs), became the preferred treatment for depression due to its com-
parable efficacy with TCAs and its superior tolerability. SSRIs were hypothesized to show
a different cardiovascular effect from TCAs due to their pharmacologic profile (Bergstrom
et al., 1988). However, there have been reports of first-degree atrioventricular block, pro-
longed QTc interval, and orthostatic hypotension in SSRI-treated patients suggesting that
SSRIs may also have important cardiac and vascular effects (de la Torre et al., 2001; Pacher
and Kecskemeti, 2004). Given that many of these studies were conducted in the laboratory
setting with brief SSRIs treatment, EMR data with detailed medication dispensing infor-
mation offer a unique opportunity to examine the effect of long-term SSRIs use on cardiac
functions in an elderly patient population.
A total of 159 patients had SSRIs dispensing records and blood pressure measures in
the EMR. In order to capture the effect of SSRIs on newly diagnosed depression patients,
we excluded patients with a history of depression at enrollment resulting in a total of 110
patients on SSRIs. To derive comparable dosages among different SSRI medications, we first
standardized medication doses using daily dose divided by the recommended minimum dose
for each medication (Damush et al., 2008). Medication dispensing data on antidepressants
displays varied patterns for both dose levels and the duration of medication use. In Figure
2.1, medication dosage and duration as well as repeated blood pressure measures from two
randomly selected patients in the analysis sample are displayed. Longitudinally measured
blood pressure levels from one year before the first SSRI dispensing to the end of patient’s
follow-up were included in our analyses. The number of blood pressure measures per patient
ranges from 1 to 104 with a median of 18.
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Figure 2.1: Time-varying medication exposure and repeated blood pressure measures from
two randomly selected patients
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2.3 Methods
2.3.1 A functional regression model for multivariate longitudinal outcomes
Let Y (k)(uij), k = 1, ...,K be the kth outcome from the ith subject of the jth visit measured
at time uij , where i = 1, ...,m and j = 1, ..., ni. Di(t) is the time-varying exposure for the
ith subject at time t and Xij is a covariate vector for the ith subject. We propose the
following functional regression model for multivariate longitudinal outcomes:

Y (1)(uij) =
∫ uij
0 Di(uij − t)w(1)(t)dt+XTijβ(1) + b
(1)
i + ε
(1)
ij
...
Y (K)(uij) =
∫ uij
0 Di(uij − t)w(K)(t)dt+XTijβ(K) + b
(K)
i + ε
(K)
ij
(2.1)
where w(1)(t), ..., w(K)(t) are unknown coefficient functions, β(1), ...,β(K) are parameters of
fixed effects for the covariatesXij ; Denote bi = (b
(1)
i , ..., b
(K)
i )
T as the random subject effects
which are used to account for both temporal correlations among the repeated measurements
from the same subject, and the correlation among the multiple outcomes. We assume
that the subject-specific random effects follow multivariate normal distribution, that is,
bi ∼ N(0,Σb) and
Σb =

σ
(11)
b ... σ
(1K)
b
... ... ...
σ
(1K)
b ... σ
(KK)
b

where σ
(kl)
b is the covariance between the random subject effects for outcomes Y
(k)(uij)
and Y (l)(uij) from the same subject measured across all visits. ε
(1)
ij , ..., ε
(K)
ij are random
errors following independent normal distribution (ε
(1)
ij , ..., ε
(K)
ij )
T ∼ N(0,Σε), where Σε =
diag(σ2ε1, ..., σ
2
εK).
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Note that the coefficient function was defined on a reversed time axis, so the origin zero
corresponds to the time when the outcome was measured. Thus w(k)(0) can be interpreted
as the effect of one unit of exposure strength at the concurrent time of the kth outcome
measure and w(k)(t) the effect of one unit exposure strength at t time units prior to the
measurement of the kth outcome. In this model framework, cumulative effects for each
outcome over uij length are modeled as
∫ uij
0
Di(uij − t)w(k)(t)dt (k = 1, ...,K)
.
In many existing applications of exposure assessment, there was plenty of evidence for
diminished effects from distant exposures, which can be linked to the compound’s half
life. Therefore, we assume that past exposure occurring a time units before the outcome
measures has a negligible effect on current outcomes. This assumption is equivalent to
requiring that the coefficient functions will smoothly go to zero at the distant boundary
of the exposure interval. One natural way to impose such a constraint is to define the
coefficient function w(t) as an integral: w(t) =
∫ −t
−a s(c)dc, t ∈ [0, a], where s(c) =
∑
vlBl(c)
and Bl(c) are some splines defined by using L interior knots equally spaced on [−a, 0], and
vl’s are the coefficients for the spline bases. Without loss of generality, in this study we
adopt the truncated cubic spline bases: 1, c, c2, c3, (c− κ1)3+, ..., (c− κL)3+. Therefore, w(t)
is the coefficient function defined on the interval [0, a] with w(a) = 0 at a distant boundary
a time units away from the time of the outcome measure, t.
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It follows that model (2.1) can be rewritten as

Y (1)(uij) = M
T
ijv
(1) +XTijβ
(1) + b
(1)
i + ε
(1)
ij
...
Y (K)(uij) = M
T
ijv
(K) +XTijβ
(K) + b
(K)
i + ε
(K)
ij
(2.2)
where
Mij = (Mij1, ...,Mij(L+4))
T
and
Mijl =
∫ uij
0
Di(uij − t)
∫ −t
−a
Bl(c)dcdt
.
Let Y = ((Y (1))T , ..., (Y (K))T )T be the response variable vectors, where Y (k) =
(Y
(k)
1,1 , ..., Y
(k)
m,nm)
T , k = 1, ...,K. Let b = ((b(1))T , ..., (b(K))T )T be the vectors of subject-
specific random effects, where b(k) = (b
(k)
1 , ..., b
(k)
m )T , k = 1, ...,K. We denote ε(k) =
(ε
(k)
1,1, ..., ε
(k)
m,nm)
T , k = 1, ...,K, and let ε = ((ε(1))T , ..., (ε(K))T )T be the random error
vectors.
We denote the design matrix with parameter vector v = ((v(1))T , ..., (v(K))T )T , where
v(k) = (v
(k)
1 , ..., v
(k)
L+4)
T in model (2.2) as M˜ = IK
⊗
M , where In is the identity matrix
of dimension n,
⊗
denotes the Kronecker product and M = [MTij ]1≤j≤ni;1≤i≤m. Similarly,
we set up the design matrix of fixed effect as X˜ = IK
⊗
X with corresponding parameter
vector β = ((β(1))T , ..., (β(K))T )T , where X = [XTij ]1≤j≤ni;1≤i≤m. The design matrix of
random effect is Z˜ = IK
⊗
Zb so that the elements of Zbbk corresponding to subject i
are equal to b
(k)
i . Therefore the functional regression model for multivariate longitudinal
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outcomes can be written in matrix form as:
Y = M˜v + X˜β + Z˜b+ ε (2.3)
where M˜ and X˜ are the design matrices of the fixed effects v and β, respectively. b ∼
N(0,Σb
⊗
Im) is the random effects vector, and random errors are ε ∼ N(0,Σε
⊗
IN ),
where N =
∑m
i=1 ni is the total number of observations.
2.3.2 Penalized spline
Model (2.3) can be regarded as a mixed model with v and β as fixed effects, and b as
random effects. The conditional distribution of the outcome variables given the random
effects, b, is normal as
Y |b ∼ N(M˜v + X˜β + Z˜b,Σε
⊗
IN )
where b ∼ N(0,Σb
⊗
Im). The best linear unbiased predictors (BLUP) of v, β and b can
be obtained by minimizing:
(Y − M˜v − X˜β − Z˜b)TR−1(Y − M˜v − X˜β − Z˜b) + bTG−1b
where R = Σε
⊗
IN and G = Σb
⊗
Im (Robinson, 1991).
The flexibility of the coefficient function can be controlled by the number of interior knots
once the spline order is fixed. A method used to avoid overfitting by the regression splines
is to impose a constraint on the coefficient of higher order basis functions as
∑L+4
l=5 (v
(k)
l )
2 <
C(k), k = 1, ...,K with a pre-chosen constant C(k) resulting in a penalized spline estimate.
Using Lagrange multiplier, imposing the penalty on v
(k)
r = (v
(k)
5 , ..., v
(k)
L+4)
T is equivalent to
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minimizing
(Y − M˜v − X˜β − Z˜b)TR−1(Y − M˜v − X˜β − Z˜b) + bTG−1b+
K∑
k=1
λ2k(v
(k)
r )
Tv
(k)
r (2.4)
for certain tuning parameter λk ≥ 0. Compared to regression splines without the constraint,
penalized splines are not as sensitive to the number of knots and location of the knots as
long as the knots are adequately spaced and the number of knots is sufficiently large (Hastie
and Tibshirani, 1990; Ruppert, 2002).
The tuning parameters λk can be chosen by cross-validation (Linhart and Zucchini,
1986). Alternatively, if we assume that v
(k)
r as a set of random variables follows a normal
distribution, v
(k)
r ∼ N(0, σ2v(k)IL), the BLUP estimates of v,β and b can be obtained by
minimizing
(Y −M˜v−X˜β− Z˜b)TR−1(Y −M˜v−X˜β− Z˜b)+bTG−1b+
K∑
k=1
1
σ2
v(k)
(v
(k)
r )
Tv
(k)
r (2.5)
which is identical to (2.4) when λ2k =
1
σ2
v(k)
. Therefore, by treating v
(k)
r as random effects
from a normal distribution, we obtain the estimate of the tuning parameter with penalized
spline using maximum likelihood instead of cross-validation. Compared with the cross-
validation approach for choosing tuning parameters through penalized estimation procedure,
ML-based methods offer computational advantageous (Kohn et al., 1991). Moreover, this
representation of the penalized spline as a BLUP in a mixed model allows the use of mixed
model estimation implemented in standard statistical software.
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2.3.3 Mixed model representation and parameter estimation
The proposed functional regression model in Section 2.3.2 using penalized spline for multi-
variate longitudinal outcomes can be written as a mixed effects model as follows:
Y = M˜fvf + X˜β + M˜rvr + Z˜b+ ε (2.6)
where vf = (v
(1)
1 , ..., v
(1)
4 , ..., v
(K)
1 , ..., v
(K)
4 )
T is the coefficient vector of lower order bases
estimated as fixed effects. vr = ((v
(1)
r )
T , ..., (v
(K)
r )
T )T is the coefficient vector of higher
order bases and can be treated as random effects as b, together with variance-covariance
matrix:
Cov

v
(1)
r
...
v
(K)
r
b
ε

=

σ2
v(1)
IL 0 0 0 0
0 ... 0 0 0
0 0 σ2
v(K)
IL 0 0
0 0 0 G 0
0 0 0 0 R

where G and R are defined previously. G measures the between-subject variation, R
measures the within-subject variation and σ2
vk
controls the smoothness of the kth coefficient
function.
In practice the time-varying exposure Di, i = 1, ...,m are usually measured at discrete
time points, e.g. daily medication intake. Therefore, Mijl =
∫ uij
0 Di(uij − t)
∫ −t
−a Bl(c)dcdt
in model (2.2) can be approximated by Mijl =
∑uij
0 Di(uij − t)(
∑−t
−aBl(c)∆c)∆t, where
∆c and ∆t are discrete time units for the coefficient function and time-varying exposures
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respectively. Substituting the discrete time notations into model (2.2), we obtain

Y (1)(uij) =
∑L+4
l=1 v
(1)
l [
∑uij
0 Di(uij − t)(
∑−t
−aBl(c)∆c)∆t] +X
T
ijβ
(1) + b
(1)
i + ε
(1)
ij
...
Y (K)(uij) =
∑L+4
l=1 v
(K)
l [
∑uij
0 Di(uij − t)(
∑−t
−aBl(c)∆c)∆t] +X
T
ijβ
(K) + b
(K)
i + ε
(K)
ij
(2.7)
.
2.3.4 Confidence interval of the coefficient function
Our primary interest is to estimate the coefficient functions w(1)(t) to w(K)(t). Based on
model (2.7), for a given time t0, w
(k)(t0), k = 1, ...,K is estimated as
wˆ(k)(t0) = (C(t0))
T vˆ(k) = (Cf (t0))
T vˆ
(k)
f + (Cr(t0))
T vˆ
(k)
r (2.8)
where
C(t0) = ((Cf (t0))
T , (Cr(t0))
T )T
Cf (t0) = (C1(t0), ..., C4(t0))
T
Cr(t0) = (C5(t0), ..., CL+4(t0))
T
and
Cl(t0) =
−t0∑
c=−a
Bl(c)∆c
is a cumulative summation of bases Bl up to time t0. vˆ
(k) includes predicted values of
random effects vˆ
(k)
r and estimated values of fixed effects vˆ
(k)
f .
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Based on the large sample theory in mixed models (Ruppert et al., 2003), the limiting
distribution of wˆ(k) evaluated at t0 is approximately normal
wˆ(k)(t0)− w(k)(t0)√
ˆvar(wˆ(k)(t0)− w(k)(t0))
∼ N(0, 1)
therefore, an approximate 100(1− α)% confidence interval for w(t0) can be constructed as
wˆ(k)(t0)± z(1− α2 )
√
ˆvar(wˆ(k)(t0)− w(k)(t0)) where
ˆvar(wˆ(k)(t0)− w(k)(t0)) = (C(t0))TCov
 vˆ
(k)
f − v(k)f
vˆ
(k)
r − v(k)r
C(t0) (2.9)
The variance-covariance matrix in equation (2.9) is a sub-matrix of the following variance-
covariance matrix (Searle et al., 2009):
Cov

vˆf − vf
βˆ − β
vˆr − vr
bˆ− b

= Cov

vˆf
βˆ
vˆr − vr
bˆ− b

with
V ar
 vˆf − vf
βˆ − β
 = ([M˜f X˜]TV −1[M˜f X˜])−
,
V ar
 vˆr − vr
bˆ− b
 = D −D[M˜r Z˜]TP [M˜r Z˜]D
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and
Cov

 vˆf − vf
βˆ − β
 ,
 vˆr − vr
bˆ− b

T
 = −([M˜f X˜]TV −1[M˜f X˜])−[M˜f X˜]TV −1[M˜r Z˜]D
where
D =

σ2
v(1)
IL 0 0 0
0 ... 0 0
0 0 σ2
v(K)
IL 0
0 0 0 G

,V = [M˜r Z˜]D[M˜r Z˜]
T +R
and
P = V −1 − V −1[M˜f X˜]([M˜f X˜]TV −1[M˜f X˜])−[M˜f X˜]TV −1
2.4 Simulation
To evaluate the performance of our proposed functional regression model for multivariate
longitudinal outcomes, simulation studies were conducted. Without loss of generality, we
considered bivariate outcomes. The timing of the exposure measured by days with treatment
or interruption in the unit of 7 days, was generated from a lognormal distribution with
mean 0.5 and standard deviation 0.8 on the log scale, i.e. log(duration) ∼ N(0.5, 0.82),
and rounded up to the nearest integer. The strengths of the time-varying exposure Di were
assumed to be constant over each treatment period (in 7 day unit), which could take values
of 0.5, 1, 1.5, 2, 2.5, or 3 during the follow-up period with equal probabilities. Two correlated
outcome (Y (1)(uij), Y
(2)(uij))
T were generated from the following model for sample size of
20
50 (i = 1, ..., 50) with random number of observations per subject of mean 10 (j = 1, ..., ni):

Y (1)(uij) = α1 +
∫ uij
0 Di(uij − t)w(1)(t)dt+ b
(1)
i + ε
(1)
ij
Y (2)(uij) = α2 +
∫ uij
0 Di(uij − t)w(2)(t)dt+ b
(2)
i + ε
(2)
ij
(2.10)
where intercepts are α1 = 72 and α2 = 122. Random variables (b
(1)
ij , b
(2)
ij )
T ∼ N(0,Σb) and
(ε
(1)
ij , ε
(2)
ij )
T ∼ N(0,Σε) have variance covariance matrix as
Σb =
 50 10
10 50
 ,Σε =
 100 0
0 400

Four coefficient functions with a pre-specified time window of 30 days were considered
(Figure 4.2), which include zero function (w(t) = 0, t ∈ [0, 30]) indicating no exposure effect
over the time window, decreasing function (w(t) = sin(pi2
t
30 +
pi
2 ), t ∈ [0, 30]) indicating
greater effect closer to event time with less effect for distant exposures, and U-shape func-
tion (w(t) = sin(3pi2
t
30 +
pi
2 ), t ∈ [0, 30]) suggesting greater effect for recent exposures and
decreasing effects for distant exposures. All coefficient functions smoothly go to zero at the
distant boundary of the exposure interval. We generated 100 data sets under each scenario
as shown in Figure 4.2.
To further evaluate our proposed method in Section 2.3.2, we compared four models:
1. Unconstrained coefficient function using regression spline (Model UR); 2. Constrained
coefficient function using regression spline (Model CR); 3. Unconstrained coefficient func-
tion using penalized spline (Model UP); 4. Constrained coefficient function using penalized
spline (Model CP). Six equally spaced interior knots were used for all models.
Parameter estimates and sample standard deviation of estimates over 100 replications
are provided in Table 2.1 to Table 2.4. Models with unconstrained coefficient function have
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Figure 2.2: Four scenarios of coefficient functions used in simulations: w(1)(t) is indicated
by solid lines; w(2)(t) is indicated by dashed lines. The coefficient functions were defined on
reversed time axes so that day zero corresponds to the time of outcome measures and in-
creasing days correspond to more distant past. Scenario 3 has identical coefficient functions
for the bivariate outcomes.
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biased estimates of σ
(1)
ε and have large sample standard deviations for σ
(1)
ε and σ
(12)
b , the
covariance between b(1) and b(2) in Model (2.10).
Table 2.1: Parameter estimates and estimated standard deviation over 100 replications un-
der Scenario 1. Model (UR): Unconstrained coefficient function; Regression spline;Model
(CR): Constrained coefficient function; Regression spline; Model (UP): Unconstrained co-
efficient function; Penalized spline; Model (CP): Constrained coefficient function; Penalized
spline
Model α1 α2
√
σ
(11)
b
√
σ
(22)
b σ
(12)
b σ
(1)
ε σ
(2)
ε
True 72 122
√
50
√
50 10 10 20
CP Mean 72.085 122.016 6.984 6.709 8.436 9.917 19.984
SD 1.128 1.802 0.824 1.361 1.162 0.291 0.692
UP Mean 72.063 122.063 6.984 6.721 10.184 7.121 19.983
SD 1.145 1.779 0.854 1.355 9.471 6.943 0.688
CR Mean 72.025 121.978 7.203 6.202 8.971 9.935 20.033
SD 1.165 1.871 0.930 2.091 0.944 0.289 0.796
UR Mean 72.060 122.047 7.013 6.768 10.616 7.114 19.977
SD 1.146 1.794 0.873 1.376 11.874 6.937 0.691
Figure 2.3 to Figure 2.6 shows 100 estimated coefficient functions obtained from the
four models under four scenarios. In each of the panels, the true coefficient function used
to generate data was in white. The estimated coefficient functions generally captures the
shape of the true functions. Instability at the tail was observed in models with unconstrained
coefficient function regardless of the types of splines. Constraining the coefficient function
seems to have reduced the variation at the tail considerably.
Mean squared errors (MSE) of the estimated coefficient functions wˆ(t) were calculated
as MSE = 130
∑t=30
t=0 (wˆ(t)− w(t))2. Table 4.2 displays, under each scenario, average mean
squared error (AMSE) for the four models. The CP model consistently yielded one of the
lowest AMSE values across all cases. Table 4.2 also displays average coverage rates (ACR)
of 95% point-wise confidence bands estimated for Model CP. In most cases, ACRs for model
CP are close to the nominal level of 0.95.
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Figure 2.3: Estimates of coefficient function under Scenario 1. White lines indicate true
coefficient function. Top left: Unconstrained coefficient function using regression spline
(Model UR); Top right: Constrained coefficient function using regression spline (Model
CR); Bottom left: Unconstrained coefficient function using penalized spline (Model UP);
Bottom right: Constrained coefficient function using penalized spline (Model CP)
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Figure 2.4: Estimates of coefficient function under Scenario 2. White lines indicate true
coefficient function. Top left: Unconstrained coefficient function using regression spline
(Model UR); Top right: Constrained coefficient function using regression spline (Model
CR); Bottom left: Unconstrained coefficient function using penalized spline (Model UP);
Bottom right: Constrained coefficient function using penalized spline (Model CP)
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Figure 2.5: Estimates of coefficient function under Scenario 3. White lines indicate true
coefficient function. Top left: Unconstrained coefficient function using regression spline
(Model UR); Top right: Constrained coefficient function using regression spline (Model
CR); Bottom left: Unconstrained coefficient function using penalized spline (Model UP);
Bottom right: Constrained coefficient function using penalized spline (Model CP)
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Figure 2.6: Estimates of coefficient function under Scenario 4. White lines indicate true
coefficient function. Top left: Unconstrained coefficient function using regression spline
(Model UR); Top right: Constrained coefficient function using regression spline (Model
CR); Bottom left: Unconstrained coefficient function using penalized spline (Model UP);
Bottom right: Constrained coefficient function using penalized spline (Model CP)
27
Table 2.2: Parameter estimates and estimated standard deviation over 100 replications un-
der Scenario 2. Model (UR): Unconstrained coefficient function; Regression spline;Model
(CR): Constrained coefficient function; Regression spline; Model (UP): Unconstrained co-
efficient function; Penalized spline; Model (CP): Constrained coefficient function; Penalized
spline
Model α1 α2
√
σ
(11)
b
√
σ
(22)
b σ
(12)
b σ
(1)
ε σ
(2)
ε
True 72 122
√
50
√
50 10 10 20
CP Mean 72.087 122.183 6.849 6.862 8.244 9.936 19.897
SD 1.340 1.561 0.952 1.154 1.903 0.303 0.532
UP Mean 72.107 122.043 6.859 6.887 8.485 5.943 19.888
SD 1.357 1.565 0.943 1.205 10.540 8.008 0.532
CR Mean 72.092 122.240 7.015 6.113 8.936 9.945 19.904
SD 1.309 1.659 1.028 2.883 0.707 0.304 0.670
UR Mean 72.100 122.029 6.860 6.898 8.477 5.939 19.882
SD 1.356 1.555 0.930 1.199 10.789 8.005 0.534
The simulation results indicate that our proposed method provided adequate parameter
estimates, were able to capture the shapes of the true coefficient functions, had low MSE
and provided satisfactory coverage rates.
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Table 2.3: Parameter estimates and estimated standard deviation over 100 replications un-
der Scenario 3. Model (UR): Unconstrained coefficient function; Regression spline;Model
(CR): Constrained coefficient function; Regression spline; Model (UP): Unconstrained co-
efficient function; Penalized spline; Model (CP): Constrained coefficient function; Penalized
spline
Model α1 α2
√
σ
(11)
b
√
σ
(22)
b σ
(12)
b σ
(1)
ε σ
(2)
ε
True 72 122
√
50
√
50 10 10 20
CP Mean 71.917 121.986 6.924 6.934 8.353 9.991 19.880
SD 1.312 1.754 0.915 1.309 1.279 0.321 0.626
UP Mean 71.914 121.981 6.940 6.937 9.554 7.590 19.872
SD 1.342 1.770 0.923 1.295 7.878 6.536 0.624
CR Mean 71.897 121.906 7.096 6.627 8.961 10.006 19.835
SD 1.336 1.810 0.950 1.627 0.718 0.325 0.634
UR Mean 71.906 121.987 6.961 6.971 9.840 7.585 19.864
SD 1.343 1.777 0.951 1.319 9.509 6.532 0.625
Table 2.4: Parameter estimates and estimated standard deviation over 100 replications un-
der Scenario 4. Model (UR): Unconstrained coefficient function; Regression spline;Model
(CR): Constrained coefficient function; Regression spline; Model (UP): Unconstrained co-
efficient function; Penalized spline; Model (CP): Constrained coefficient function; Penalized
spline
Model α1 α2
√
σ
(11)
b
√
σ
(22)
b σ
(12)
b σ
(1)
ε σ
(2)
ε
True 72 122
√
50
√
50 10 10 20
CP Mean 72.229 122.140 6.810 7.011 8.333 9.943 19.898
SD 1.323 1.857 0.842 1.274 1.638 0.357 0.583
UP Mean 72.194 121.954 6.801 6.967 8.007 5.987 19.894
SD 1.366 1.856 0.845 1.293 9.799 7.985 0.584
CR Mean 72.173 122.042 6.974 6.552 8.861 9.954 19.867
SD 1.366 1.908 0.929 2.014 0.841 0.359 0.647
UR Mean 72.177 121.995 6.806 6.962 7.385 5.983 19.886
SD 1.359 1.823 0.837 1.289 10.809 7.978 0.581
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Table 2.5: Average mean squared error (AMSE) using the four estimation methods and av-
erage coverage rates (ACR) of 95% point-wise confidence bands estimated using the model
with constrained coefficient function and penalized spline over 100 replications. Model
(UR): Unconstrained coefficient function; Regression spline;Model (CR): Constrained coeffi-
cient function; Regression spline; Model (UP): Unconstrained coefficient function; Penalized
spline; Model (CP): Constrained coefficient function; Penalized spline
Scenario Coefficient function AMSE ACR
Estimation method (UR) (CR) (UP) (CP) (CP)
Scenario 1 w(1)(t) 0.010 0.006 0.007 0.006 0.950
w(2)(t) 0.027 0.015 0.018 0.014 0.953
Scenario 2 w(1)(t) 0.008 0.006 0.007 0.006 0.954
w(2)(t) 0.035 0.015 0.028 0.021 0.935
Scenario 3 w(1)(t) 0.009 0.008 0.007 0.008 0.909
w(2)(t) 0.035 0.017 0.022 0.017 0.952
Scenario 4 w(1)(t) 0.010 0.006 0.007 0.006 0.950
w(2)(t) 0.027 0.015 0.018 0.014 0.953
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2.5 Data application
In this section we revisit the motivating data set we described in Section 2.2. We used the
following model to examine the effects of antidepressants on diastolic and systolic blood
pressure:

DBP (uij) = X
T
ijβ
(D) +
∫ uij
0 Di(uij − t)w(D)(t)dt+ b
(D)
i + ε
(D)
ij
SBP (uij) = X
T
ijβ
(S) +
∫ uij
0 Di(uij − t)w(S)(t)dt+ b
(S)
i + ε
(S)
ij
(2.11)
where DBP (uij) and SBP (uij) represent diastolic and systolic blood pressure measures for
ith subject at time uij . X
T
ij represent covariates including intercept, time, gender and the
use of antihypertensive. Di(t) is the time-varying SSRIs exposure. w
(D)(t) and w(S)(t) are
the coefficient functions for diastolic and systolic blood pressure measures respectively. b
(D)
i
and b
(S)
i are correlated random subject effects. ε
(D)
ij and ε
(S)
ij are random errors. Repeated
blood pressure measures from one year before the first SSRIs dispensing to one year after
the last SSRIs dispensing were included in the analysis, resulting in a total number of 1714
measures for each blood pressure type.
We estimated the coefficient functions under various pre-specified exposure time windows
using truncated cubic bases with 6 equally spaced interior knots. Parameter estimates of
fixed and random effects and variance components are included in Table 4.4. The estimates
are relatively stable across different time windows. Since these models with different time
intervals have the same number of parameters, the best fitting model can be selected based
on the likelihood. The model with a 60-day exposure window has the smallest negative
likelihood and is selected to be the best fitting model (Table 4.4). Subject effects of systolic
blood pressure have greater variability (σˆ
(S)
b = 20.48(SD = 1.23)) than diastolic (σˆ
(D)
b =
10.44(SD = 0.65)) with a covariance of 8.58. The random error associated with systolic
31
blood pressure also has larger variability (σˆ
(S)
ε = 20.03(SD = 0.36)) than diastolic blood
pressure (σˆ
(D)
ε = 12.15(SD = 0.22)).
Figure 2.7 shows estimated coefficient functions with confidence bands under various
exposure windows. It can be seen that all confidence bands contain the zero line, which
indicates that there is no significant SSRIs effect on diastolic or either systolic blood pres-
sures. We observe that estimated coefficients show less fluctuations under longer exposure
time window. When we increased the number of interior knots to 8 under the 360-day
exposure time window, similar shape of the estimated coefficient functions were observed
as compared with using 6 interior knots 2.8. Therefore, the finding of no significant SSRIs
effect on BP is not likely to be sensitive to the choice of the number of knots.
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(d) Time window: 360 Days
Figure 2.7: Estimated coefficient functions with corresponding confidence bands under var-
ious exposure time windows
34
0 50 100 150 200 250 300 350
−
1.
0
−
0.
5
0.
0
0.
5
1.
0
Days
Figure 2.8: Estimated coefficient functions with corresponding confidence bands under ex-
posure time window of 360 Days with 8 interior knots
2.6 Conclusion
In this Chapter, we developed functional regression models for multivariate outcomes with
time-varying exposures using penalized splines. Our simulation studies indicate adequate
performances for parameter estimation and inferences. Our proposed model extends previ-
ous methods in several ways. First, this model includes multivariate longitudinally measured
outcomes and estimate the effects of exposure on all the outcomes simultaneously. Second,
our model framework includes a constraint at the boundary of the exposure interval and
hence reduces the estimation variability. By expressing the functional model into a mixed
model representation, we demonstrate that parameter estimation and inference procedures
can be implemented using standard statistical software packages.
We demonstrated the application of the proposed method in a group of SSRIs users in
estimating the association between SSRIs exposure and longitudinal blood pressure mea-
sures. The proposed model framework can be readily applied to other medication groups
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to determine whether medication use is associated with longitudinally measured health
outcomes.
One limitation of this study is that we considered independent identical within-subject
random errors for each type of outcome. However, a wider range of correlation structures
could be embedded into within-subject random errors in the current modeling framework.
For example, cor(ε
(k)
ij , ε
(k)
ij′ ) = q(|uij − uij′ |), k = 1, ...,K, where q is a correlation function
taking values between -1 and 1. Such an assumption allows varying correlation over time
but may introduce more computational complexity. Another direction for future work is to
extend the coefficient function regression model to generalized mixed model settings, where
the correlated outcomes can be from more general exponential distributions rather than
normal distributions.
In summary, we proposed a functional regression model framework for multivariate
outcomes with time-varying exposures using penalized spline. The proposed methods per-
formed adequately in simulation studies. With the increasing availability of electronic med-
ical records of medication dispensing data, our proposed methods can be readily applied to
other medication dispensing data to determine whether medication use have a long-term
association with longitudinally measured health outcomes.
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Chapter 3
Flexible models for comparing cumulative effects of time-dependent exposures
3.1 Introduction
One of the major focuses of pharmacoepidemiologic studies is to determine whether ex-
posure to certain medications is associated with adverse health outcomes. The increasing
use of electronic medical records (EMR) in health care systems has made patients’ medi-
cation dispensing data available, including detailed information on doses and duration. In
publications in the medical journals, many analyses were conducted using methods that
summarize medication exposure by using current dose (Smitten et al., 2008), average daily
dose (Wolfe et al., 2006) , or as simple sum of past exposures (Stranges et al., 2006). These
methods all assume, explicitly or implicitly, that the impact of past exposure on event risk
does not depend on the timing of the exposure. In addition, these methods do not combine
the effects from both intensity and duration of time-varying exposures.
Breslow et al. (1983) and Thomas (1988) proposed the use of a weighted cumulative
exposure (WCE) to summarize time varying exposures. Abrahamowicz et al. (2006) used
the parametric WCE framework within the Cox’s proportional hazards (PH) model to
study the association between a time-varying exposure and event risk. They relied on
a clinically viable weight function with more weight for recent exposures and gradually
decreasing to zero weight thereafter, and a scale parameter for controlling the rate of change
in weights over time. Interesting applications with weight function modeled by simple
parametric functions can also be found in works by VACEK (1997) , Langholz et al. (1999),
and Richardson (2009). However, without sufficient prior knowledge of the medication’s
pharmacokinetic properties, imposing a specific parametric form of the weight function may
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result in invalid conclusion if the parametric form is mis-specified (VACEK, 1997). Instead
of restricting the weight function to a parametric form, other approaches were proposed to
estimate the functional form of the weight function using flexible nonparametric methods.
Hauptmann et al. (2000) introduced a weight function model using cubic B-spline within
generalized linear models to examine the time-dependent effects of smoking histories on
lung cancer. A constrained maximization algorithm was then used to jointly estimate
regression coefficient and spline coefficients. Sylvestre and Abrahamowicz (2009) extended
the parametric WCE Cox model (Abrahamowicz et al., 2006) to nonparametric models using
a regression spline-based method to assess the association between exposure to psychotropic
drugs and fall-related injuries. The authors proposed re-parameterization of the WCE so
that it can be implemented by survival analysis with time-dependent covariates in standard
statistical packages.
Recently, many extensions have been made in defining WCE. For example, Berhane
et al. (2008) proposed a tensor product spline model to jointly model age, latency and
exposure response effects for protracted time-dependent occupational exposure histories in
the Colorado plateau uranium miners cohort. Gasparrini (2013) noted out that equivalent
approaches were previously established in time series analysis. Analogous to the weight
function, the definition of a distributed lag function was introduced in distributed lag models
(DLMs) and distributed lag nonlinear models (DLNMs) in time series analysis.
An existing problem, not addressed thus far is that in clinical practice patients receive
different types of medications intended for the same medical condition and it is of interest to
compare the effects of these medication exposures on relevant health outcomes. However,
little work has been done in comparing the effect of multiple medication exposures over
an extended period on time to event outcomes. In this Chapter, we extend the regression
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spline-based method in Sylvestre and Abrahamowicz (2009) to model WCE in multiple
exposures settings where weight functions for each exposure type can be considered.
In Section 3.2, we describe data from a primary care depression cohort as a motivating
example for our proposed model. In Section 3.3, we present a flexible WCE model for
multiple exposures on a survival outcome and describe procedures for parameter estimation,
hypothesis testing and pointwise confidence bands for the weight functions. We present the
results of a simulation study in section 3.4 to evaluate the performance of our proposed
model. In Section 3.5, we apply the new method to the example data set and compare the
risk of coronary artery disease (CAD) between two types of antidepressants. We include a
discussion of our method in Section 3.6.
3.2 A primary care depression screening cohort
Our interest is to compare the risk of CAD between two common types of antidepressants,
tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) (Zell-
weger et al., 2004). There have been reports of increased risk of CAD events in TCA users
(Pacher et al., 1999), but no increased CAD risk for SSRI users in postmenopausal women
(Smoller et al., 2009). However, none of the previous studies considered dose or duration of
antidepressants exposure in the analysis. As it is widely known that patients on depression
treatments receive different dosages and may take these medications intermittently, it is
therefore of interest to compare whether cumulative exposures to SSRIs and TCAs were
associated with different CAD risks.
In our data set, there were 203 patients taking TCAs and 162 patients taking SSRIs
during the follow-up time. From January 1991 to June 1993, those patients attending
primary care clinics at the Wishard Health Services were enrolled into a depression screening
study (Callahan et al., 1994). Electronic medical records on these patients from enrollment
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to December 31, 2010 were extracted from the Regenstrief Medical Record System (RMRS)
(McDonald et al., 1999). The RMRS is one of the first electronic medical record systems
in the country and has been actively used for research purposes. Originally implemented
in 1973 and used continuously since then, the RMRS serves as the day-to-day electronic
medical record system at Wishard Hospital and its community clinics — the third largest
safety-net health care system in the U.S. The RMRS routinely captures laboratory results,
narrative reports, orders, medications, radiology reports, registration information, nursing
assessments, vital signs, EKGs and other clinical data. The medical records also include
comprehensive medication dispensing information capturing medication name, daily dose,
beginning and ending dates for each dispensing record.
In this elderly population, patients were also at risk of dying. Patients who died of my-
ocardial infarction (MI) without previous CAD should also be considered as CAD events.
In order to combine such information, death dates were extracted from Medicare/Medicaid
data set and causes of death were obtained from death certificates provided by the Indiana
State Department of Health. Therefore, our primary outcome, a hard CAD event, was
defined as the occurrence of any of the following events in the medical record or Medi-
care/Medicaid data during the follow-up period: (a) fatal MI; (b) laboratory evidence of
acute MI (Creatine kinase-myocardial band isoenzyme value > 3.0 ng/ml or troponin value
> 0.3 ug/L); and (c) diagnosis of CAD (ICD-9 codes 410-414,429.2).
To derive comparable dosages among different medications, we first standardized medi-
cation doses using daily dose divided by the recommended minimum dose for each medica-
tion (Damush et al., 2008). Medication dispensing data on antidepressants displays varied
patterns for both dose levels and for the duration of medication use. In Figure 4.1, med-
ication dosage and duration as well as event time from four randomly selected patients in
the analysis cohort were displayed. Such patterns of medication exposure demonstrate the
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need for statistical methods that can account for the varying exposure pattern and identify
potential differences in the effects of exposure patterns over time on disease risk.
Figure 3.1: Medication exposure of four randomly selected patients with event time (denoted
by square) or censoring time (denoted by diamond)
3.3 Method
3.3.1 Cox’s PH model with time-dependent WCE
Let X(t) be the exposure level measured at time t. Let M(u) be a summary measure of
exposure up to time u: M(u) =
∫ u
0 f(X(t))dt, where f is a function that summarizes past
exposures. The form of f reflects how the intensity and duration of past exposure are
related to the outcome of interest.
41
The challenge is how to choose a functional form for f(.) so that the summary exposure
M(u) can best describe the cumulative effect of past exposures. A simple choice for the
function f(.) included the un-weighted cumulative dose, i.e. M(u) =
∫ u
0 X(t)dt, which
assumes that past exposures have the same effect on the outcome no matter when the
exposure happened.
Alternatively, a more flexible approach of summarizing past exposures can be achieved
by assuming
M(u) =
∫ u
0
w(u− t)X(t)dt
where w(u− t) is an unknown weight function to be estimated from the data. Notice that
the time axis in the weight function is defined as the length of time away from the endpoint,
so that weight function defined on [0, a] would associate with history exposures within a
units of time from an endpoint u. Without loss of generality, we assume that past exposure
outside of the a units has negligible effect on the survival outcome by restricting the weight
function to 0 for exposures beyond a unit length of time from the endpoint.
The weight function can be modeled using a polynomial function which will impose
a strong prior assumption on the functional form. An alternative is to use splines with
interior knots and make all pieces join smoothly to increase flexibility. The flexibility of
the spline function is determined by the number of interior knots m and spline order q.
Among different forms of spline bases, the B-spline (De Boor, 2001) is commonly used for
its computational stability. In this paper, we use cubic B-splines (q = 4) which provide
sufficiently smooth estimates with continuous first two derivatives.
Once the number of interior knots of the cubic B-spline bases m is determined, the
weight functions can be expressed as a linear combination of the B-spline bases: w(u− t) =∑m+4
j=1 θjBj(u − t) (De Boor, 2001; Giorgi et al., 2003). Using such B-spline bases for the
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weight function, the cumulative exposure to a medication can be written as
M(u) =
∫ u
0
m+4∑
j=1
θjBj(u− t)X(t)dt
In real applications, the exposure X(t) is often measured at discrete time points. There-
fore the cumulative exposure M(u) up to time u can be expressed as
M(u) =
u∑
t=0
m+4∑
j=1
θjBj(u− t)X(t)
Suppose there are K medications of interest. Let Ik = I{med = k} be the indicator
function for patients taking the kth medication, k = 1, ...,K, i.e. Ik = 1 if a patient is on
the kth medication, and Ik = 0 otherwise. The cumulative exposure which allows different
forms of the weight functions for different medications can be written as:
M(u) =
u∑
t=0
m+4∑
j=1
(θ1j +
K∑
k=2
θkjIk)Bj(u− t)X(t)
where θkj , j = 1, ...,m + 4 represent differences in weight functions between the k
th medi-
cation and the 1st medication group. Therefore, w1(u− t) =
∑m+4
j=1 θ1jBj(u− t) represents
the weight function of the 1st medication group and wk(u− t) =
∑m+4
j=1 (θ1j + θkj)Bj(u− t)
represents the weight function of the kth(k > 1) medication group.
If the outcome variable is time to certain event, a Cox’s PH model can be fitted to assess
the effect of the medication exposure on the event risk. The model involving medication
exposure history as well as the types of medication can be written as:
h(u|X(u), Z(u)) = h0(u) exp
[
β1M(u) +
K∑
1
β2kIk +
S∑
s=1
ηsZs(u)
]
(3.1)
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where β1 represents the effect of the weighted cumulative exposure on the hazard in people
who took the first medication. β2k, k = 1, ...,K represents the medication difference com-
pared to the reference group adjusting for other covariates in the model. For parameter
identifiability, we set β21 = 0, which in essence sets the first medication group as the refer-
ence group. Zs(u), s = 1, ..., S are other covariates. Notice that, if K = 1 then our model
is consistent with the WCE model proposed by Sylvestre and Abrahamowicz (2009).
3.3.2 Estimation procedures
The estimation of the survival model (3.1) can be implemented by introducing time-dependent
covariates Dj(u) =
∑u
t=0Bj(u− t)X(t), j = 1, ...,m+ 4, where Dj(u) can be thought of as
the exposure weighted by a set of predetermined basis functions Bj(u− t). Therefore, the
proposed model (3.1) using the variables Dj , medication main effect and interactions can
be rewritten as
h(u|X(u), Z(u)) = h0(u) exp[
m+4∑
j=1
β1θ1jDj(u) +
K∑
k=2
β2kIk (3.2)
+
K∑
k=2
m+4∑
j=1
β1θkjDj(u) ∗ Ik +
S∑
s=1
ηsZs(u)]
Notice that β’s and θ’s cannot be estimated separately from the above model. Instead,
their products:
γkj = β1θkj , k = 1, . . . ,K
are estimable from the model. The new parameters combine both shape and scale informa-
tion in the weight functions into a single parameter.
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Correspondingly, model (3.2) becomes
h(u|X(u), Z(u)) = h0(u) exp[
m+4∑
j=1
γ1jDj(u) +
K∑
k=2
β2kIk (3.3)
+
K∑
k=2
m+4∑
j=1
γkjDj(u) ∗ Ik +
S∑
s=1
ηsZs(u)]
With a scale difference of β1, the weight function for the 1
st medication group can now be
represented as w1(u− t) =
∑m+4
j=1 γ1jBj(u− t) and wk(u− t) =
∑m+4
j=1 (γ1j + γkj)Bj(u− t)
for the kth(k > 1) medication group.
With the new time-varying covariates, Dj(u), model (3.3) can be fitted using procedures
for Cox’s PH model with time dependent covariates in any standard statistical software. As
we mentioned before, when the order of splines is fixed, the flexibility of the estimated spline
function is determined by the number of interior knots. Akaike information criterion(AIC)
(Akaike, 1974) can be used to select the model with best predictive performance from models
with different numbers of interior knots. The AIC adapted to a Cox PH model is defined
as: AIC = −2ln(PL) + 2p, where PL is the partial likelihood and p is the number of
estimable parameters (Abrahamowicz et al., 2012). The model with the smallest AIC is
selected as the best fitting model to the data at hand. Comparisons of WCE models using
the minimum AIC criteria were shown to identify the true model in the vast majority of
simulation studies conducted by Abrahamowicz et al. (2012).
3.3.3 Hypothesis testing
In pharmacoepidemiologic studies, multiple medications are often available for the same
medical condition and thus the comparison of adverse event risk among different medication
users is of great interest. Several hypotheses may be proposed for model (3.3). The first
hypothesis is whether the K medications share the same weight function, i.e., whether
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past exposures influence current risk in the same way for all medications. Based on model
(3.3), linear combinations of B-spline bases with coefficients γkj , j = 1, ...,m+ 4 represent
differences in weight functions between the kth medication and the reference group, where
k = 2, ...,K.
Therefore, the hypothesis of no difference in weight function can be stated as:
H0: γkj = 0, k = 2, . . . ,K, j = 1, . . . ,m+ 4
H1: otherwise
where m is the number of interior knots within the time interval [0, a].
Under the assumption that the spline basis is chosen as a prior, it had been shown
that in Cox PH models the partial likelihood score statistics are asymptotically normal,
hence Likelihood Ratio Test (LRT) using partial likelihood functions can be used to test
this hypothesis since the model under the null hypothesis of equal weight function is nested
within the full Model (3.3) (Andersen and Gill, 1982). Asymptotic normality of model
parameters was also previously established (Andersen and Gill, 1982). However, when
model selection is used, the LRT statistics are conditional on the selected model, where the
degree of freedom of the Chi-square statistic is no longer fixed and depends on the number
of selected interior knots. Standard LRT ignoring model selection may lead to inflated type
I error (Abrahamowicz et al., 1996; Hurvich and Tsai, 1990; Mahmud et al., 2006). We
will assess the impact of the violation to the fixed-basis assumption in simulation studies
in Section 3.4.
Another hypothesis of interest is whether the medications have the same main effect, i.e.
β2k = 0, k = 2, ...,K. Wald tests using the asymptotic normality of the partial maximum
likelihood estimates can be used to test these hypotheses.
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3.3.4 Pointwise confidence band for the estimated weight function
In order to evaluate the variation of the estimated weighted functions, nonparametric boot-
strap re-sampling can be used to construct 95% confidence band of estimated weight func-
tion (Efron, 1979). Subjects can be re-sampled with replacement with their medication
exposure history and endpoint from the original data set to create re-sampled data sets of
the same size. For each of the bootstrap samples the proposed WCE models can be fitted
with the same number of interior knots as in the original data set. The empirical distribu-
tion of the point estimates of weight function is constructed and 95% pointwise confidence
bands can be computed using the bootstrap samples. The confidence band using bootstrap
re-sampling accounts for the variation of regression coefficients as well as the additional
variation introduced by the selection of knots.
3.4 Simulation study
To evaluate the performance of our proposed model, we simulated data sets using a prospec-
tive cohort design to compare the effects of two different medications on the risk of an
adverse event. We considered two different sample sizes (200 and 500 patients) with equal
probability of taking one of two medications.
3.4.1 Generating medication exposures and survival data
Medication exposures were generated in a one-year follow-up window with days being the
unit of time. The duration of treatment period or interruption periods, in 7 days intervals,
was generated from a lognormal distribution with mean 0.5 and standard deviation 0.8 on
the log scale, i.e. log(duration) ∼ N(0.5, 0.82), and rounded up to integer values. Daily
doses were assumed to be constant over each treatment period but can vary during the
follow up period with equal probability of 0.5, 1, 1.5, 2, 2.5,or 3. We also generated a
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time-fixed variable for age at baseline from normal distribution with mean 70 and variance
3.
We considered the combinations of six true weight functions for medications, A and B,
with a pre-specified time window of 180 days (Figure 3.2), similar to the weight functions
used by Sylvestre and Abrahamowicz (2009) in the single exposure setting . The six sce-
narios for weight functions include maximum medication effect closer to event time with
decreasing effect for more distent exposures (Scenarios 1 and 2), peak effect followed by
decreasing effect (Scenario 3), increasing effect followed by decreasing trend in an inverted
U function (Scenario 4), constant effect (Scenario 5) and increasing effect for distent expo-
sures (Scenario 6). The combinations of these six scenarios for each of the two medications
create 21 unique weight function patterns for the two medications. For convenience, we
denote the combination of scenario i for Medication A and scenario j for Medication B as
AiBj , where i, j = 1, ..., 6, j ≥ i.
Time to event was generated using the permutation algorithm designed and validated
for simulating survival times conditional on time-dependent covariates (Sylvestre and Abra-
hamowicz, 2008).
3.4.2 Simulation results
We considered models with the number of interior knots ranging from one to three, which
implies five to seven bases using cubic B-spline bases. For each of the 1000 samples simulated
under a given scenario, we used the AIC criteria to select the number of knots for the model.
Assessing parameter estimates
In our simulation setting with two medications, we drop the subscript k of main effect β2k
in our models. The estimable parameters from model (3.3) include β2, η1, and γkj , k =
1, 2; j = 1, . . . ,m + 4. In order to estimate the coefficients of WCE, we use normalized
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Figure 3.2: Six scenarios of true weight function for each medication. The time axis is
the reversed time since exposure. The origin Days = 0 corresponds to current time, and
increasing Days correspond to more distant past. All the weight functions are normalized.
weight functions:
a∑
τ=0
w(τ) = 1
we can estimate the effect of WCE as:
βˆ11 =
a∑
τ=0
m+4∑
j=1
γˆ1jBj(τ)
and
βˆ21 =
a∑
τ=0
m+4∑
j=1
(γˆ1j + γˆ2j)Bj(τ)
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Parameter estimates are presented in Table 3.1. For a given scenario, average parameter
estimate, estimated standard deviation and empirical standard deviation from 1000 simula-
tions were presented for each coefficient. Since exp(β2) represents the hazard ratio between
medication A and medication B given the same cumulative exposure, we also reported 95%
confidence coverage rate for β2.
Table 3.1 shows that the estimated coefficients are unbiased across all scenarios in both
sample sizes. As expected, bias and standard deviation estimates, both model-based and
empirical based, decrease when sample size increases. The estimated standard deviation
closely tracks the empirical standard deviation with both sample sizes.
Figure 3.3 displays a random sample of 100 estimated weight functions with the corre-
sponding true weight functions in thick white. Each estimated weight function was calcu-
lated based on the selected model using AIC criteria for a given simulated data set. In most
scenarios, the estimated weight functions were able to capture the shape of the true weight
functions and can be distinguished between the two medication groups. As expected, the
estimate weight functions show considerable over-fitting bias in the tails, which is a known
feature of B-splines (Hastie and Tibshirani, 1986).
Hypothesis testing on weight functions
Table 3.2 presents the proportion of the 1000 simulations when the LRT rejects the null
hypothesis of no difference in weight functions (p < 0.05) for the 21 unique weight function
combinations. Therefore, entries on the diagonal represent estimated type I error rates and
entries in the off-diagonal setting are empirical power of the LRT. Two different rejection
rates were calculated under each scenario. In the first set of calculation, we fixed the number
of interior knots to three, while in the second method, the degree of freedom of the LRT
statistics depends on the number of interior knots selected using AIC.
50
A1B1 A1B2 A1B3 A1B4 A1B5 A1B6
A2B1 A2B2 A2B3 A2B4 A2B5 A2B6
A3B1 A3B2 A3B3 A3B4 A3B5 A3B6
A4B1 A4B2 A4B3 A4B4 A4B5 A4B6
A5B1 A5B2 A5B3 A5B4 A5B5 A5B6
A6B1 A6B2 A6B3 A6B4 A6B5 A6B6
Figure 3.3: A random sample of 100 normalized estimated weight functions (Sample
size=500). Thick white lines indicate the true weight functions . Blue lines indicate weight
functions for Medication A and red lines indicate weight functions for Medication B.
Simulation results show that empirical type I error rates for the fixed method are closer
to the nominal level of α = 0.05 and empirical type I error rates using the flexible method
are slightly inflated. Furthermore, in almost all the situations, estimated power is high for
both methods except for scenario A2B3, where the two weight functions were very similar
(Figure 3.2).
Assessing pointwise confidence band
Without loss of generality, we assess the precision of the estimated weight function using
confidence band under the null hypothesis of no difference between the two medications.
Figure 3.4 shows four randomly selected bootstrap confidence bands when both medications
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have inverted U weight functions (Scenario A4B4). Solid lines indicate true weight functions
and dotted ones indicate estimated weight functions from the original simulated data set.
Each panel presents the estimated upper and lower 95% confidence band (dashed line).
Coverage proportion (CP), which is the percentage of equally spaced sampling points where
the confidence bands cover the true weight function, was also calculated (Wahba, 1983).
Average coverage proportion (ACP) over 100 simulated data sets was 94.6%, close to the
nominal level of 95% .
Figure 3.4: Four randomly selected bootstrap confidence bands of inverted U weight function
(Scenario A4B4, Sample size=500): True weight function used to simulated data is denoted
by solid line; Dotted line is the estimated weight function from original simulated data set;
Dashed lines are upper or lower bound of 95% bootstrap confidence band
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Table 3.1: Estimated coefficients based on 1000 simulations with sample size 200 and 500
β11 (True 2.0) β
2
1 (True 2.0) η1 (True 0.5) β2 (True 1.0)
Sce. M. M.SD E.SD M. M.SD E.SD M. M.SD E.SD M. M.SD E.SD Cov.R
Sample size 200
A1B1 2.02 0.69 0.74 2.03 0.76 0.80 0.52 0.05 0.05 0.99 0.48 0.51 0.94
A1B2 1.96 0.69 0.72 1.98 0.84 0.88 0.51 0.05 0.05 1.00 0.52 0.56 0.94
A1B3 2.02 0.69 0.72 2.03 0.83 0.88 0.52 0.05 0.05 1.02 0.51 0.54 0.94
A1B4 1.98 0.70 0.75 1.97 0.77 0.82 0.52 0.05 0.05 1.02 0.47 0.51 0.93
A1B5 2.01 0.71 0.74 2.02 0.71 0.74 0.52 0.05 0.05 1.02 0.47 0.49 0.95
A1B6 2.04 0.75 0.77 2.08 0.67 0.69 0.52 0.05 0.05 1.04 0.47 0.48 0.95
A2B2 2.04 0.74 0.79 2.04 0.81 0.86 0.52 0.05 0.05 1.04 0.53 0.55 0.94
A2B3 2.06 0.74 0.77 2.04 0.80 0.84 0.52 0.05 0.05 1.02 0.52 0.55 0.94
A2B4 2.03 0.77 0.80 2.01 0.77 0.81 0.52 0.05 0.05 1.05 0.51 0.54 0.94
A2B5 2.04 0.77 0.83 2.01 0.70 0.75 0.52 0.05 0.05 1.06 0.51 0.50 0.96
A2B6 2.02 0.81 0.84 2.04 0.67 0.70 0.52 0.05 0.05 1.06 0.51 0.53 0.95
A3B3 2.01 0.73 0.75 1.99 0.80 0.84 0.52 0.05 0.05 1.04 0.52 0.54 0.93
A3B4 1.99 0.75 0.76 2.01 0.77 0.79 0.52 0.05 0.05 1.01 0.50 0.51 0.94
A3B5 2.05 0.77 0.82 2.03 0.71 0.77 0.52 0.05 0.05 1.07 0.50 0.51 0.94
A3B6 1.99 0.80 0.85 2.00 0.67 0.71 0.52 0.05 0.05 1.05 0.50 0.52 0.95
A4B4 2.06 0.70 0.79 2.05 0.78 0.84 0.52 0.05 0.05 1.01 0.46 0.48 0.94
A4B5 2.04 0.70 0.76 2.03 0.72 0.79 0.51 0.05 0.05 1.05 0.47 0.50 0.94
A4B6 2.04 0.74 0.78 2.04 0.66 0.70 0.52 0.05 0.05 1.06 0.46 0.48 0.94
A5B5 2.02 0.65 0.68 2.04 0.73 0.77 0.52 0.05 0.05 1.02 0.47 0.48 0.95
A5B6 1.97 0.67 0.73 2.02 0.66 0.70 0.51 0.05 0.05 1.02 0.46 0.49 0.94
A6B6 2.05 0.63 0.63 2.07 0.68 0.69 0.52 0.05 0.05 1.03 0.46 0.47 0.95
Sample size 500
A1B1 2.00 0.41 0.42 2.00 0.44 0.45 0.51 0.03 0.03 1.01 0.31 0.32 0.94
A1B2 2.01 0.42 0.41 2.01 0.48 0.50 0.51 0.03 0.03 1.01 0.34 0.35 0.96
A1B3 2.00 0.42 0.43 2.01 0.47 0.48 0.51 0.03 0.03 1.01 0.33 0.34 0.94
A1B4 2.01 0.42 0.44 2.02 0.43 0.45 0.51 0.03 0.03 1.02 0.29 0.29 0.95
A1B5 2.02 0.42 0.43 2.03 0.40 0.41 0.51 0.03 0.03 1.02 0.29 0.29 0.95
A1B6 1.98 0.45 0.45 2.01 0.37 0.37 0.51 0.03 0.03 1.02 0.29 0.29 0.95
A2B2 2.02 0.44 0.43 2.01 0.46 0.48 0.51 0.03 0.03 1.04 0.34 0.35 0.94
A2B3 2.03 0.44 0.44 2.06 0.46 0.46 0.51 0.03 0.03 1.01 0.33 0.33 0.95
A2B4 2.03 0.46 0.46 2.02 0.43 0.43 0.51 0.03 0.03 1.04 0.31 0.31 0.95
A2B5 2.00 0.45 0.47 1.99 0.39 0.41 0.50 0.03 0.03 1.02 0.31 0.32 0.94
A2B6 2.00 0.49 0.51 2.01 0.37 0.39 0.51 0.03 0.03 1.03 0.30 0.30 0.96
A3B3 2.01 0.44 0.43 2.00 0.46 0.49 0.51 0.03 0.03 1.01 0.33 0.33 0.95
A3B4 2.00 0.45 0.47 1.99 0.43 0.43 0.51 0.03 0.03 1.02 0.30 0.32 0.94
A3B5 2.01 0.45 0.46 2.01 0.39 0.41 0.51 0.03 0.03 1.03 0.30 0.31 0.94
A3B6 2.01 0.48 0.48 2.01 0.37 0.37 0.51 0.03 0.03 1.03 0.30 0.30 0.96
A4B4 2.01 0.42 0.43 2.01 0.44 0.46 0.51 0.03 0.03 1.02 0.29 0.30 0.94
A4B5 2.00 0.43 0.43 2.01 0.41 0.43 0.51 0.03 0.03 1.01 0.29 0.29 0.96
A4B6 2.00 0.45 0.45 2.02 0.37 0.37 0.51 0.03 0.03 1.01 0.29 0.29 0.95
A5B5 2.00 0.39 0.39 2.01 0.41 0.43 0.51 0.03 0.03 1.01 0.29 0.31 0.93
A5B6 2.01 0.41 0.42 2.02 0.37 0.38 0.51 0.03 0.03 1.02 0.28 0.29 0.94
A6B6 2.04 0.37 0.39 2.04 0.38 0.39 0.51 0.03 0.03 1.01 0.29 0.29 0.95
M. is the mean of estimates across 1000 simulation results
M.SD is the mean of model based standard deviation across 1000 simulation results
E.SD is empirical standard deviation of 1000 estimated coefficients
Cov.R is the coverage rate of 95% confidence intervals across 1000 simulation results
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Table 3.2: Hypothesis test of equal weight functions (sample size=500). Entries in the table
are proportion of simulations where the null hypothesis is rejected based on 1000 simulations
MedicationB
MedicationA S.1 S.2 S.3 S.4 S.5 S.6
β2 = 0
S.1 Fixed 0.065 0.968 0.859 0.998 0.845 1.000
Flexible 0.082 0.983 0.884 0.999 0.896 1.000
S.2 Fixed 0.048 0.288 1.000 1.000 1.000
Flexible 0.065 0.330 1.000 1.000 1.000
S.3 Fixed 0.050 1.000 1.000 1.000
Flexible 0.050 1.000 1.000 1.000
S.4 Fixed 0.041 0.933 1.000
Flexible 0.068 0.962 1.000
S.5 Fixed 0.067 0.973
Flexible 0.057 0.988
S.6 Fixed 0.046
Flexible 0.086
β2 = 1
S.1 Fixed 0.060 0.962 0.832 0.999 0.851 1.000
Flexible 0.071 0.974 0.853 0.999 0.893 1.000
S.2 Fixed 0.046 0.301 1.000 1.000 1.000
Flexible 0.073 0.354 1.000 1.000 1.000
S.3 Fixed 0.051 1.000 1.000 1.000
Flexible 0.069 1.000 1.000 1.000
S.4 Fixed 0.065 0.953 1.000
Flexible 0.058 0.966 1.000
S.5 Fixed 0.045 0.978
Flexible 0.064 0.992
S.6 Fixed 0.063
Flexible 0.066
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3.5 Data application
In this section we revisit the example data we described in Section 3.2 and apply the
proposed model to the data from the primary care depression cohort. Our interest is to
compare the risk of CAD between patients on SSRIs to those on TCAs. Patients with
CAD before antidepressant use were excluded from the analysis. Therefore, the analysis
data set contained 365 subjects in total with 203 patients taking TCAs and 162 patients on
SSRIs. Entry time in the survival analysis was the first time when a patient was dispensed
an antidepressant (Suissa, 2007). Event time was calculated using CAD date if a patient
had CAD or death date if a patient died of CAD. Censoring time was calculated using last
clinical encounter date for those who were alive or death data if a patient died of other
disease. A total of 123 patients (33.7%) developed hard CAD during the follow-up.
The median survival time is 1448 days in this sample. In the WCE model framework,
we considered varying windows of medication effects from 60 days up to 1920 days with the
length of window doubling each time. For each pre-specified time window, we estimated
WCE models with three fixed interior knots uniformly spaced within the time window. In
addition to medication variables, all models also adjusted for five covariates for patients’
characteristics: age at first antidepressant use, years of education, sex, race and a binary
indicator for smoking status.
Table 3.3 summarizes the corresponding AIC as well as p-values from hypothesis tests
for each pre-specified time window. The model with 240 days of potential medication effect
had the smallest AIC. Regardless, results from LRT and Wald tests for all the models
indicate that the there is no difference between the two weight functions and there is also
no difference between the main effect of SSRIs and TCAs.
Figure 3.5 shows the estimated weight functions with 240-day window for both SSRIs
and TCAs user as well as their 95% bootstrap pointwise confidence bands. In general,
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Table 3.3: Model results using different medication exposure windows from 60 days up to
1920 days
Time window AIC Hypothesis test Hypothesis test
(Days) of no weight function difference of no medication main effect
60 1438.91 0.61 0.99
120 1437.97 0.52 0.91
240 1434.96 0.29 0.94
480 1436.90 0.44 0.99
960 1438.10 0.51 0.80
1920 1439.19 0.31 0.76
the estimated weight functions of SSRIs and TCAs are similar across the entire time win-
dow, which is consistent with the hypothesis test results. Both 95% pointwise confidence
bands include zero across the entire exposure window. Overall, in this cohort, we found no
difference in CAD risk between patients taking SSRIs and those taking TCAs.
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Figure 3.5: Estimated weight functions with 240-day window for antidepressant SSRIs and
TCAs user as well as 95 percent bootstrap confidence band: solid lines indicate estimated
weight functions and dashed lines indicate 95% confidence bands (SSRIs in blue and TCAs
in red); Dashed horizontal line is the zero line.
3.6 Conclusion
In observational studies, especially in post-marketing surveillance studies monitoring med-
ications for long-term adverse events, it is important to utilize patients’ medication history
when comparing different classes of medications for the same indication. In this Chapter,
we extend the flexible WCE model proposed by Sylvestre and Abrahamowicz (2009) for
single exposure to the comparison of multiple exposures. The use of flexible weight func-
tions using spline bases not only offers flexibility in summarizing cumulative exposures,
but also provides information on how the risk of adverse event is impacted by the tim-
ing of the exposures. Furthermore, parameter estimation for the proposed model can be
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implemented using standard statistical packages for survival analysis with time-dependent
covariates making the proposed models applicable to many data applications.
Our simulation studies demonstrate adequate performance of the proposed methods in
parameter estimation as well as hypothesis testing using fixed number of knots. However,
simulation results also revealed inflated Type I error rates when the test was conditional
on AIC criteria selected number of knots. Further research is needed to determine a more
appropriate distribution for the LRT statistics when using a model selection criteria to
determine the number of knots.
Some extensions can be made to the proposed methods in future studies. The models
considered here did not use any constraint on the weight function when using spline bases.
As a result, the estimated weight functions can be negative as seen in the simulations and
the analysis of the antidepressant data. In practice, such negative weight functions are
difficult to interpret and it would be ideal to start the model framework with the non-
negative requirement in the model set-up. Parameter estimation and hypothesis testing
procedures need to be modified to accommodate such a constraint.
In aging studies involving patients with multiple chronic conditions, the majority of
patients were found to be on multiple medications at any given time. Thus it is important
that statistical models take into account all medications a patient has been exposed in order
to detect potential risk to adverse events. Another significant development based on our
methods is to model interactions among the different medications patients are taking.
In summary, we proposed a flexible model to compare cumulative exposures of multi-
ple medications over time. Parameter estimation and hypothesis tests can be conducted
using standard statistical software packages for survival analysis. The proposed methods
performed adequately in simulation studies. With the increasing availability of electronic
medical records of medication dispensing data, our proposed methods can be readily applied
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to to medication dispensing data to detect differences in adverse event risk among different
classes of medications.
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Chapter 4
A penalized Cox PH model with time-varying exposures and interaction term
4.1 Introduction
In recent pharmacoepidemiological studies, the increasing use of electronic medical records
(EMR) in health care systems has made available patients medication dispensing data with
detailed information on medication names, dosage and duration. Such particular medication
exposure poses challenges to existing statistical model because both the exposure status and
its intensity vary over time, named as time-varying exposure in general. Moreover, patients
often receive multiple types of medication, sequentially or concurrently, intended for the
same medical condition. For example, depressed patients may switch from one type of
antidepressants to another if the treatment fails to show satisfactory efficacy. Or patients
with hypertension may take more than one class of antihypertensive medications at the same
period. Therefore, assessing the effect of multiple exposures and their potential interaction
effects brings additional complexity to the statistical model.
To fully utilize the information of such time-varying exposure, Breslow et al. (1983) and
Thomas (1988) were among the first ones to propose the concept of weighted cumulative
exposure (WCE) by assigning predetermined weights to time-varying exposures and summa-
rizing it into scalers. Applications using WCE by pre-defined parametric functions can also
be found in works by Abrahamowicz et al. (2006), VACEK (1997) , Langholz et al. (1999),
and Richardson (2009). Various approaches have also been proposed using nonparametric
splines to estimate the weight function in generalized linear models (Berhane et al., 2008;
Hauptmann et al., 2000) and Cox proportional hazard models (Gasparrini, 2013; Sylvestre
and Abrahamowicz, 2009). However, to the best of our knowledge, few study discussed
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multiple time-varying exposures, let alone the interactions between them, in WCE model
setting.
In the meanwhile, functional data analysis is also an active field to study time-varying
exposures. Functional regression models have been developed for functional covariates,
where the functional coefficients can be equivalent to the weights for time-varying exposures
in weighted cumulative exposure models. Many functional regression models include only
one single functional covariate, such as Zhang et al. (2007), Schipper et al. (2008) and
Bhadra et al. (2012). Goldsmith et al. (2012) and Ferraty and Vieu (2009) include two
or more functional covariates through additive models. If the assumption of additivity
of the effects of multiple functional covariates is challenged, it is natural to add covariate
interaction effects. To the best of our knowledge, not much work has been done to study the
interaction effects between functional covariates. Fuchs et al. (2015) generalized functional
linear model and proposed a penalized scalar-on-functions regression with interaction term,
which extended the model with only main effects in Wood (2011). The estimation of
interaction effects between functional covariates has not received much attention in the
survival setting.
Additionally, when modeling the effect of exposure to medication or environmental tox-
ins, there are biological reasons that exposures occurring long time before an outcome might
have negligible influence, so that the coefficient function should be bounded toward zero
at a distant boundary. Schipper et al. (2008) proposed two constraints on the coefficient
function making the coefficient function zero at zero dose and imposing monotonicity such
that higher dose leads to more adverse outcomes.
In this chapter, we proposed a penalized Cox PH model with functional covariates and
interaction term. In particular, the coefficient functions for functional covariates have been
expanded using cubic B-spline basis for the main effects and tensor product splines for the
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interaction effect. Because boundary issues may happen in estimating the coefficient func-
tions when regression spline was used (Sylvestre and Abrahamowicz, 2009), ridge penalties
were added to smooth coefficient functions for the main effect and coefficient surface for
the interaction effect. Studies about penalized Cox PH model and its associated hypothesis
tests can be found in Gray (1992, 1994), Therneau et al. (2003) and Perperoglou (2014).
The coefficient functions and coefficient surface were estimated by maximizing penalized
log partial likelihood. Hypothesis tests of no interaction effect or no effect of time-varying
exposure were also discussed based on Wald’s method. The performance of the model is
evaluated in simulations.
This chapter is organized as follows. Section 2 describes data from a primary care
depression study as a motivating example. Section 3 introduces the penalized Cox PH
model with interaction term, parameter estimation and hypothesis test. Section 4 presents
results of simulation studies. In section 5, we apply the proposed model to the real data
set and estimate the association between two types of time-varying antidepressant exposure
and the risk of coronary artery disease.
4.2 A primary care depression screening cohort
From January 1991 to June 1993, 3767 elderly patients attending primary care clinics at the
Wishard Health Services were enrolled into a depression screening study (Callahan et al.,
1994). Electronic medical records on these patients from enrollment to December 31, 2010
were extracted from the Regenstrief Medical Record System (RMRS) (McDonald et al.,
1999). The RMRS is one of the first electronic medical record systems in the country and
has been actively used for research purposes. The RMRS routinely captures laboratory
results, narrative reports, orders, medications, radiology reports, registration information,
nursing assessments, vital signs, EKGs and other clinical data. The medical records include
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comprehensive medication dispensing information capturing medication name, daily dose,
beginning and ending dates for each dispensing record.
Antidepressant is one of the most commonly prescribed medication groups in the United
States (Lindsley, 2012). An older class of antidepressants, tricyclic antidepressants (TCAs),
have been shown to have detrimental effect on cardiovascular function by inhibiting car-
diovascular Na(+), Ca(2+) and K(+) channels often leading to life-threatening arrhythmia
(Glassman, 1984; Jefferson, 1975). A newer class of antidepressants, selective serotonin
reuptake inhibitors (SSRIs), became the preferred treatment for depression due to its com-
parable efficacy with TCAs and its superior tolerability. SSRIs were hypothesized to show
a different cardiovascular effect from TCAs due to their pharmacologic profile (Bergstrom
et al., 1988). However, there have been reports of first-degree atrioventricular block, pro-
longed QTc interval, and orthostatic hypotension in SSRI-treated patients suggesting that
SSRIs may also have important cardiac and vascular effects (de la Torre et al., 2001; Pacher
and Kecskemeti, 2004). Given that many of these studies were conducted in the labo-
ratory setting with brief antidepressant treatment, EMR data with detailed medication
dispensing information offer a unique opportunity to examine the effect of long-term use on
cardiac functions in an elderly patient population. Moreover, none of the previous studies
considered the comprehensive information of time-varying antidepressants exposure in the
analysis. As it is widely known that patients on depression treatments receive different
dosages and may take these medications sequentially, it is therefore of interest to examine
whether the time-varying exposures to TCAs or SSRIs and their interaction are associated
to risk of CAD.
In the data set, there were 930 depression patients with at least one dispensing record
for antidepressants. We included patients who were taking TCA or SSRI throughout the
follow-up period. The time when they initiated the medication was considered as time
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zero in our survival analysis. To derive comparable dosages among different medications,
we first standardized medication doses using daily dose divided by the recommended min-
imum dose for each medication (Damush et al., 2008). Dispensing data of antidepressants
display various patterns for both dose intensity and duration of treatment. In Figure 4.1,
medication dosage and duration from four typical patients in the analysis cohort were dis-
played: patient who took TCA exclusively throughout the follow-up period; patient who
take SSRI exclusively; patient who switched from TCA to SSRI; patient who took TCA
and SSRI sequentially. Such patterns of medication exposure demonstrate the need for sta-
tistical methods that can account for the varying exposure pattern and identify potential
differences in the effects of exposure patterns over time on disease risk.
64
Figure 4.1: Examples of medication exposure from four typical patients. Upper left: patient
who took TCA exclusively; Upper right: patient who take SSRI exclusively; Lower left:
patient who switched from TCA to SSRI; Lower right: patient who took TCA and SSRI
sequentially
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4.3 Methods
4.3.1 A penalized Cox PH model with time-varying exposures and interaction
term
Suppose {DA(u)} and {DB(u)} are denoted as two series of time-varying exposures, A and
B, up to time u. In practice, the time-varying exposures are usually measured at discrete
time points, e.g. daily medication intake, thus that exposure history can be discretized as
Dk(1), Dk(2), ..., Dk(u), k = A,B. X is an n× p matrix for other covariates, with Xi a row
vector of covariates for individual i. α = (α1, ..., αp)
T is a vector of covariate coefficients.
Then the Cox Proportional Hazards (PH) model that defines the hazard at time u given
the history of time-varying exposures {Dk(u)} and other covariates X is expressed as:
h(u|{DA(u)}, {DB(u)},X) =h0(u)exp(
∫ u
0
wA(u− t)DA(t)dt
+
∫ u
0
wB(u− t)DB(t)dt
+
∫ u
0
∫ u
0
wint(u− t, u− s)DA(t)DB(s)dtds
+Xα)
(4.1)
where h0(u) is an unspecified baseline hazard function. wA(u − t) and wB(u − s) are
functional coefficients for time-varying exposures DA(t) and DB(s). In many existing ap-
plications of exposure assessment, there was plenty of evidence for diminished effects from
distant exposures. Thus, we assume that past exposure occurring certain units before has a
negligible effect on current event. Equivalently the coefficient functions will smoothly go to
zero at the distant boundary of the exposure interval. We impose such constraint through
integral by defining the coefficient function as wk(t) =
∫ −t
−a sk(c)dc, t ∈ [0, ak], k = A,B,
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so that wk(ak) = 0. [0, ak] is a supporting interval covering current time 0 and ak time
units before. sk(c) =
∑Lk+4
l=1 βklBkl(c). Lk is the number of interior knots that are equally
spaced on the supporting intervals. Without loss of generality, we use cubic B-spline bases,
Bkl(u− t), l = 1, ..., Lk + 4, and βkl are the associated coefficients of spline bases.
The coefficient surface wint(u− t, u− s) between two time-varying exposures is modeled
by nonparametric bivariate function using tensor product basis as, wint(u − t, u − s) =∑
βint,lrBlr(u− t, u−s), where Blr(u− t, u−s) is obtained by forming all pairwise products
between the cubic B-spline basis functions as Blr(u − t, u − s) = Bl(u − t)Br(u − s), l =
1, ..., Lint + 4, r = 1, ..., Lint + 4, resulting a total of (Lint + 4)× (Lint + 4) basis functions,
assuming same Lint interior knots of both directions for simplicity. If there is only one time-
varying exposure then our model is consistent to the WCE model proposed by Sylvestre
and Abrahamowicz (2009).
Denote
Mk(u) = (Mk1(u), ...,MkLk+4(u)), k = A,B
with
Mkl(u) =
∫ u
0
Dk(u− t)
∫ −t
−ak
Bkl(c)dcdt, l = 1, ..., Lk + 4
Denote
N(u) = (N11(u), ..., N1(L3+4)(u), ..., N(L3+4)(L3+4)(u))
with
Nlr(u) =
∫ u
0
∫ u
0
Blr(t, s)DA(u− t)DB(u− s)dtds, l, r = 1, ..., (L3 + 4)
Let
βk = (βk1, ..., βkLk+4), k = A,B
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and
βint = (βint,11, ..., βint,1Lk+4, ..., βint,Lk+4Lk+4)
be the coefficient vectors for B-spline basis and tensor product basis. It follows that model
(4.1) can be rewritten as
h(u) = h0(u)exp(MA(u)βA +MB(u)βB +N(u)βint +Xα) (4.2)
The above model using regression splines can be very useful and can be implemented
using standard software. However, without any constraint on the coefficients, regression
splines are more unstable and sensitive to the number and location of knots than are penal-
ized splines. Hastie and Tibshirani (1986) gave examples where the sensitivity of regression
splines to knot locations can have problems. The estimates from regression spline shows
rapid, unrealistic fluctuations probably caused by substantial over-fitting of the data (Gray,
1992). The un-penalized estimation of βs lead to wiggly fits and imposing constraints on
βs might rectify this problem. One type of constraints on estimated βs is to satisfy the
condition β′kβk < Ck, k = A,B, int for certain choice of Ck, which is called ridge penalty
and is well known in generalized linear model. Therefore, a penalized Cox model can be
fitted by applying restrictions on the coefficients of basis functions and subtracting a ridge
penalty from the log likelihood, becoming the penalized partial likelihood (Perperoglou,
2014):
ppl(α,β,λ) = pl(α,β)− 1
2
λAβ
T
AβA −
1
2
λBβ
T
BβB −
1
2
λintβ
T
intβint (4.3)
where pl(α,β) is the log partial likelihood. The factor 12 is introduced for mathematical
convenience. The parameter estimates βˆs are obtained by maximizing penalized partial
likelihood (4.3) when non-negative smoothing parameters λs are specified. A Newton-
Raphson procedure can now be used to estimate the penalized regression coefficients.
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It is of crucial to determine the smoothing parameters λs. If λs are too small, then the
βs are slightly shrunk to zero. If λs approach infinite, the estimated βs would eventually
become zero indicating that the estimated coefficient function would become zero lines and
the estimated coefficient surface would become flat zero surface. The most common way to
optimize the penalty weight is to conduct a grid search over several values of λs, usually
spanning from very small values to quite large values. Then the models are fitted with the
different weights and the optimal choice is considered the one that maximizes some sort of
criterion such as Akaike information criteria (AIC) with AIC = 2ppl(α,β1,β2,β3) − 2df
(Perperoglou, 2014). In practice, it is usually more convenient to specify the degree of
freedom (df) and to solve for the values of the smoothing parameters (Buja et al., 1989).
Hurvich et al. (1998) suggested a corrected AIC (AICC), which used n(df+1)/(n−(df+2))
(n is the total number of events in Cox PH model) as the correction term in place of df in
AIC, because they showed that using AIC lead to models with an excess number of degrees
of freedom. We have considered both AIC and AICC in simulation studies.
The connection between smoothing parameter and degree of freedom is suggested by
Gray (1992). The total degree for the model is
df = trace[I(η)H−1(η,λ)]
where η is a full set of parameters (α,β). I(η) is the usual observed information matrix
for the partial likelihood. H(η,λ) = −∂2pl(η)/∂η2 = I(η) +P (λ) and P (λ) is the second
derivative matrix of the penalty function, which is a block-diagonal matrix with block λkIk
corresponding to the βk. Ik is identity matrix of the same dimension with βk.
Since the time-varying exposure Dk(t), k = A,B are usually measured at discrete time
points in practical such as daily medication intake. Therefore, Mkl(u) can be approximated
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as
Mkl(u) =
u∑
0
Dk(u− t)(
−t∑
−ak
Bkl(c)∆c)∆t, l = 1, ..., Lk+4
where ∆c is the discrete time unit for the coefficient function and ∆t is the discrete time
unit for time-varying exposures. Similarly, Nlr(u) can be approximated as
Nlr(u) =
u∑
0
u∑
0
Blr(t, s)DA(u− t)DB(u− s)∆t∆s, l, r = 1, ..., (Lint + 4)
where ∆t and ∆s are the discrete time units for time-varying exposures.
4.3.2 Hypothesis test
Based on Model (4.1), one hypothesis of interest is that the effects of time-varying exposures
DA(t) and DB(t) are additive and there is no interaction effect, leading to a flat zero
coefficient surface. Thus the null hypothesis states as βint = 0. It is also of interest to test
whether time-varying exposure DA(t) or DB(t) has effect on survival outcome, so that the
null hypothesis states as βA = 0 or βB = 0.
This section discusses general linear hypotheses of the form Cη = 0, where C has full
row rank. Following Gray (1992), a Wald type test statistic is defined as
(Cη)T (CH−1CT )−1(Cη)
But in the penalized Cox model, this test will be conservative if a standard Chi-square
statistic is assumed. Gray (1992) showed that under the null the expectation of the test
statistic is approximately equal to
trace[(CH−1CT )−1(CH−1IH−1C−T )] (4.4)
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Then, equation (4.4) will be considered as the generalized degree of freedom of the test.
4.4 Simulation
4.4.1 Simulation setup
To evaluate the performance of our proposed model, simulation studies were conducted.
Three groups were considered based on types of exposure. Subjects in the first group
exclusively exposed to medication A, subjects in the second group exclusively exposed to
medication B and subjects in the third group exposed to both medication A and B over the
follow-up period, sequentially or concurrently. Assuming equal sample size in each group,
three levels of total sample size were investigated: 300, 450 and 600.
The timing of the exposure measured by days with treatment or interruption in the
unit of 7 days, was generated from a lognormal distribution with mean 0.5 and standard
deviation 0.8 on the log scale, i.e. log(duration) ∼ N(0.5, 0.82), and rounded up to the
nearest integer. The intensity of the time-varying exposure was assumed to be constant
over each treatment period (in 7 day unit), which could take values of 0.005, 0.01, 0.015,
0.02, 0.025, or 0.03 during the follow-up period with equal probabilities.
Several coefficient functions with a pre-specified time window of 90 days were considered:
1) zero function (w(t) = 0, t ∈ [0, 90]) indicating no exposure effect over the time window, 2)
decreasing function (w(t) = sin(pi2
t
90 +
pi
2 ), t ∈ [0, 90]) indicating greater effect closer to event
time with less effect for distant exposures, and U-shape function (w(t) = sin(pi t90 + pi), t ∈
[0, 90]) suggesting greater negative effect for middle exposures and less effects for recent
and distant exposures. All true coefficient functions smoothly go to zero at the distant
boundary of the exposure interval. The coefficient functions were defined on reversed time
axes so that day zero in Figure 4.2 corresponds to the time of cumulative effects measured
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Figure 4.2: Four scenarios of coefficient functions used in simulations: w(A)(t) is indicated
by solid lines; w(B)(t) is indicated by dashed lines. The coefficient functions were defined
on reversed time axes so that day zero corresponds to the time of outcome measures and
increasing days correspond to more distant past. Scenario 3 has identical coefficient func-
tions.
and increasing days correspond to more distant past. We generated 200 data sets under
each scenario as shown in Figure 4.2.
Coefficient surface with a pre-specified time window of 30 days were generated from
two individual surfaces as shown in Figure 4.3. The interaction surface has higher values
along the diagonal, indicating that medications have larger interaction effect when taken
simultaneously and such effect decreases while approaching to the distant boundary. Similar
to the definition of coefficient function, the interaction surface was also defined on reversed
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time axes. X-axis indicates the exposure time for medication A and y-axis represents
medication B.
Survival outcomes were generated based on the following formula with various combi-
nation of corresponding coefficient functions:
h(u|{DA(u)}, {DB(u)}) =h0(u)exp(
∫ u
0
wA(u− t)DA(t)dt
+
∫ u
0
wB(u− t)DB(t)dt
+
∫ u
0
∫ u
0
wint(u− t, u− s)DA(t)DB(s)dtds) (4.5)
Permutation algorithm was used, which is designed and validated for simulating survival
times with time-varying covariates Sylvestre and Abrahamowicz (2008).
4.4.2 Simulation results
We simulated 200 data sets and the proposed Model (4.1) was fitted with six equally spaced
interior knots for each coefficient function and one interior knots for coefficient surface. AIC
and AICC were both used to select smoothing parameters. Since we adopted cubic B-spline
basis, the maximum degrees of freedom for coefficient function and coefficient surface are
10 and 25 respectively.
Estimates wˆA, wˆB and wˆint were obtained for each scenario. The average mean squared
error for the interaction is calculated as
avgMSEint =
1
200
200∑
r=1
1
30× 30
30∑
t=1
30∑
s=1
(wint(t, s)− wˆint(t, s))2
(4.6)
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(a) Two surfaces with associated contour plots used to generate interaction surface
 0  5 10 15 20 25 30−
0.
00
5
 
0.
00
0
 
0.
00
5
 
0.
01
0
 
0.
01
5
 
0.
02
0
 0
 5
10
15
20
25
30
Medication A in Days
M
ed
ica
tio
n 
B 
in
 D
ay
s
(b) Interaction surface (3D)
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(c) Interaction surface (Contour)
Figure 4.3: Two 3D surfaces with associated contour plots used to generate the interaction
surface with a pre-specified time window of 30 days. Surfaces were defined on reversed
time axes, where x-axis indicates the exposure time for medication A and y-axis represents
medication B. Upper surface has constant highest values on the diagonal. Middle surface
has decreasing values with increasing days. Lower surface is a weighted combination of
upper surface and middle surface.
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where the index r represents the replicates. avgMSEA and avgMSEB are defined analo-
gously as
avgMSEk =
1
200
200∑
r=1
1
90
90∑
t=1
(wk(t)− wˆk(t))2, k = A,B
(4.7)
Results of avgMSE are presented in Table 4.1. The variability of estimated coefficient
functions and coefficient surface decreases as sample size increases. Models that use cor-
rected AIC (AICC) to select smoothing parameter tend to have slightly better performance
compared with models using AIC. Also, the original shape of coefficient function influences
the estimation in terms of avgMSE.
Figure 4.4 to Figure 4.15 show the estimated coefficient functions and mean of estimated
coefficient surface from Scenario 1 to Scenario 4 with sample size of 300, 450 and 600. In
each panel of coefficient function, the true coefficient functions are denoted as white solid
lines and 200 estimates as black lines. Less fluctuation was observed as sample size increases.
The estimated functions or surface were able to capture the shape of the true ones. Figure
4.16 and Figure 4.16 show the sample-based mean and point-wise confidence bands across
200 replications. The 2.5% and 97.5% point-wise quantiles are denoted as red dashed lines.
Mean estimates are denoted as blue dashed lines and the true coefficient functions used to
simulate data are denoted as black solid lines.
Table 4.2 presents the empirical type I errors of hypothesis tests under sample size of
450 over 200 replications. Two hypothesis tests of interest were conducted. One is to
test whether there is an interaction between two time-varying exposures. Under the null
hypothesis of no interaction, the coefficient surface is expected to be a zero flat surface.
Wald test in penalized Cox’s PH model discussed in Section 4.3.2 was performed by testing
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Table 4.1: Average mean squared error (avgMSE) (×10−5) of coefficient functions and
coefficient surface estimated by penalized Cox PH method over 200 replications
Scenarios
Coefficient Sample size Selection method S1 S2 S3 S4
wA(t) 300 (AIC) 4.40 4.76 9.11 9.06
300 (AICC) 3.58 3.86 8.84 8.26
450 (AIC) 3.08 3.66 5.72 5.43
450 (AICC) 2.96 3.33 5.44 5.24
600 (AIC) 2.26 2.30 5.05 4.46
600 (AICC) 2.16 2.14 4.77 4.07
wB(t) 300 (AIC) 7.91 12.4 7.97 14.7
300 (AICC) 6.93 12.1 7.59 14.0
450 (AIC) 5.60 9.60 5.82 9.39
450 (AICC) 5.31 9.41 5.68 9.15
600 (AIC) 4.44 8.08 4.67 7.71
600 (AICC) 4.37 8.07 4.50 7.61
wint(t) 300 (AIC) 2.45 2.28 2.37 1.84
300 (AICC) 1.83 1.89 2.00 1.52
450 (AIC) 1.29 1.20 1.88 1.17
450 (AICC) 1.19 1.08 1.68 1.07
600 (AIC) 0.81 0.93 1.24 0.88
600 (AICC) 0.77 0.89 1.16 0.80
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Figure 4.4: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 1 with sample size of 300. True coefficient functions are denoted as white solid
lines.
77
Figure 4.5: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 1 with sample size of 450. True coefficient functions are denoted as white solid
lines.
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Figure 4.6: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 1 with sample size of 600. True coefficient functions are denoted as white solid
lines.
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Figure 4.7: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 2 with sample size of 300. True coefficient functions are denoted as white solid
lines.
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Figure 4.8: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 2 with sample size of 450. True coefficient functions are denoted as white solid
lines.
81
Figure 4.9: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 2 with sample size of 600. True coefficient functions are denoted as white solid
lines.
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Figure 4.10: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 3 with sample size of 300. True coefficient functions are denoted as white solid
lines.
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Figure 4.11: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 3 with sample size of 450. True coefficient functions are denoted as white solid
lines.
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Figure 4.12: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 3 with sample size of 600. True coefficient functions are denoted as white solid
lines.
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Figure 4.13: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 4 with sample size of 300. True coefficient functions are denoted as white solid
lines.
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Figure 4.14: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 4 with sample size of 450. True coefficient functions are denoted as white solid
lines.
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Figure 4.15: Estimated coefficient functions and mean of estimated coefficient surface in
Scenario 4 with sample size of 600. True coefficient functions are denoted as white solid
lines.
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(a) Scenario 1
(b) Scenario 2
Figure 4.16: Sample point-wise confidence bands for Scenario 1 and Scenario 2. Red dashed
lines are 2.5% and 97.5% point-wise quantiles. Blue dashed lines are mean estimates. The
true coefficient functions are denoted as black solid lines.
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(a) Scenario 3
(b) Scenario 4
Figure 4.17: Sample point-wise confidence bands for Scenario 3 and Scenario 4. Red dashed
lines are 2.5% and 97.5% point-wise quantiles. Blue dashed lines are mean estimates. The
true coefficient functions are denoted as black solid lines.
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Table 4.2: Empirical type I errors of Wald tests under sample size of 450 across 200 repli-
cations
Scenarios
Null hypothesis (Selection method) S1 S2 S3 S4
No interaction (AIC) 0.06 0.07 0.05 0.03
No interaction (AICC) 0.05 0.07 0.05 0.03
No effect of D(A)(t) (AIC) 0.06 0.04 - -
No effect of D(A)(t) (AICC) 0.06 0.04 - -
βint,lr = 0, l, r = 1, ..., 5. In Scenario 1 and Scenario 2, wAs are flat zero lines indicating
no main effect from exposure A. Therefore, hypothesis tests for the main effect of A were
also performed under Scenario 1 and Scenario 2 by testing βAl = 0, l = 1, ..., 10. Table 4.2
shows that all the empirical type I errors were close to the nominal level 0.05 and selection
methods using AIC or AICC have comparable rate.
4.5 Application
In this section we revisit the motivating data set we described in Section 2 and apply the
proposed model. Our primary interest is to examine the effects of two classes of antide-
pressants on the risk of coronary artery disease (CAD). The analysis data set contained
297 subjects in total with 160 patients taking TCAs exclusively, 93 patients taking SSRIs
exclusively and 44 patients taking both. In this elderly population, patients were also at
risk of dying. Patients who died of myocardial infarction (MI) without previous CAD are
also considered as CAD events. In order to combine such information, death dates were
extracted from Medicare/Medicaid data set and causes of death were obtained from death
certificates provided by the Indiana State Department of Health. Therefore, our primary
outcome, a hard CAD event, was defined as the occurrence of any of the following events
in the medical record or Medicare/Medicaid data during the follow-up period: (a) fatal
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MI; (b) laboratory evidence of acute MI (Creatine kinase-myocardial band isoenzyme value
> 3.0 ng/ml or troponin value > 0.3 ug/L); and (c) diagnosis of CAD.
Entry time in the survival analysis was the first time when a patient was dispensed
an antidepressant (Suissa, 2007). Event time was calculated using CAD date if a patient
had CAD or death date if a patient died of CAD. Censoring time was calculated using last
clinical encounter date for those who were alive or death data if a patient died of other
disease. A total of 91 patients (30%) developed hard CAD during the follow-up.
In the model, some potential covariates such as gender and age at first serve of medica-
tion were adjusted. Table 4.3 shows descriptive statistics among three groups. According
to previous simulation result, models with selection method of corrected AIC (AICC) have
better estimation results, thus we applied models with AICC and estimated the coefficient
functions and coefficient surface under various pre-specified exposure time windows using
cubic B-spline basis with 10 basis functions and cubic tensor product basis with 25 basis
surfaces. Table 4.4 summarizes estimates of some coefficients and p-values obtained from
hypothesis tests under various pre-specified relevant time (in month). The length of pre-
specified time interval for interaction surface measures the longest drug-drug interaction
interval. For example, 18-month time interval for coefficient surface indicates that no in-
teraction effect between SSRI at current time and TCA at 18 months before, or vice versa.
By assuming that influence time for drug-drug interaction is not longer than that for med-
ication itself, we only present results where time interval of coefficient function is equal or
longer than the interval of coefficient surface. Regardless of time interval, results from the
Wald tests for all the models indicate that the there is no interaction surface.
Table 4.5 shows under various time intervals, estimates of female and age at first serve
of antidepressants and P-values of hypothesis tests of time-varying antidepressants effect on
risk of CAD from models given no interaction term. Antidepressant class of TCAs shows
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Table 4.3: Comparison of demographic information among three groups.P-value is calcu-
lated using ANOVA for continuous variables and Chi-square test for binary variables
SSRI (n=93) TCA (n=160) TCA&SSRI (n=44) P-value
Age at first serve Mean(SD) 73.62(6.15) 70.21(6.88) 69.73(6.39) 0.0001
Years of Education Mean(SD) 8.91(2.67) 8.76(2.83) 8.48(3.45) 0.7094
Female (%) 80(86.02) 120(75) 35(79.55) 0.1147
African-American (%) 69(74.19) 115(71.88) 24(54.55) 0.0484
Smoke at any time (%) 31(33.33) 69(43.13) 16(36.36) 0.2827
CAD Events (%) 27(29.03) 53(33.13) 11(25) 0.5389
marginally significance. Figure 4.18 shows estimated coefficient functions for both TCAs
and SSRIs under various pre-specified time interval. Black lines indicate TCAs. Red lines
indicate SSRIs. The timing-varying effect of TCAs can be explained as TCAs is marginally
associated with the risk of CAD event and TCAs taken recently have larger influence than
that taken more distant before.
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Figure 4.18: Estimates of coefficient functions for both TCA and SSRI under various pre-
specified time interval. Black lines indicate TCA. Red lines indicate SSRI
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4.6 Discussion
In this chapter, we proposed a penalized Cox proportional hazards (PH) model with func-
tional covariates and interaction term, which can be used to examine the effects of time-
varying exposures and their interaction effect on survival outcome. Flexible weighted cu-
mulative exposure (WCE) model proposed by Sylvestre and Abrahamowicz (2009) and
penalized scalar-on-functions regression model by Fuchs et al. (2015) provide insight into
the formula of our model. Penalized Cox PH model discussed by Perperoglou (2014) and
Gray (1992) provide methods of parameter estimation. Furthermore, parameter estimation
can be implemented using standard statistical packages for survival analysis with time-
dependent covariates making the proposed models applicable to many data applications
(Therneau et al., 2003). Simulation studies demonstrate adequate performance of the pro-
posed methods in parameter estimation as well as hypothesis testing. The application of
the proposed method in a cohort of depressed patients shows that there is no interaction
between two classes of antidepressants. The proposed model framework can be readily ap-
plied to other medication groups into determine whether medication use is associated with
other survival health outcomes.
The models considered here have constraint on the right end of coefficient functions for
biological and identification reason. In the flexible WCE model of single exposure, Sylvestre
and Abrahamowicz (2009) imposed such constraint by forcing the last two coefficients of
basis functions to be zero, leading to the loss of degree of freedom. Compared with their
method, the way we put the constraint doesn’t have such issue. Another strength is that
the units between two types of exposure are not necessarily to be converted to the same
magnitude. In our model, SSRIs and TCAs are two classes of antidepressants. Within each
class standard dosage was derived among antidepressants because they were considered as
one type of exposure, but it is unnecessary to adjust dosage between TCAs and SSRIs.
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Another significant development based on our methods is to model interactions among the
different medications patients are taking. In aging studies involving patients with multiple
chronic conditions, the majority of patients were found to be on multiple medications at any
given period. Thus it is important that statistical models take into account all medications
a patient has been exposed in order to detect potential risk to adverse events.
Therneau et al. (2003) discussed the natural connection between penalized Cox PH
model and frailty model. One possible extension of our model is that the penalized pa-
rameters can be considered as random effects. In our model, we did a grid search to
select smoothing parameter based on AIC and AICC. Thus, our model is computational
demanding and highly depends on the intensity of grid. By assuming penalized parameters
from standard Gaussian distribution, the model may have advantage of using frailly model
methodology to optimize the penalty weight.
In summary, we proposed a penalized Cox PH model with two time-varying exposures
and their interaction. The proposed methods performed adequately in simulation studies.
With the increasing availability of electronic medical records of medication dispensing data,
our proposed methods can be readily applied to other medication dispensing data to de-
termine whether multiple medication use have a long-term association with survival health
outcomes.
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Chapter 5
Conclusion
We have studied several flexible models related to time-varying exposures. The proposed
methodologies are applicable to many medical research areas.
First, in Chapter 2, we developed functional regression models for multivariate out-
comes with time-varying exposures using penalized splines. Our simulation studied indi-
cate adequate performances for parameter estimation and inferences. Our proposed model
extended previous methods in several ways. First, this model included multivariate lon-
gitudinally measured outcomes and estimate the effects of exposure on all the outcomes
simultaneously. Second, our model framework included a constraint at the boundary of the
exposure interval and hence reduces the estimation variability. By expressing the functional
model into a mixed model representation, we showed that parameter estimation and infer-
ence procedures can be implemented using standard statistical software packages. We also
demonstrated the application of the proposed method in a group of SSRIs users in estimat-
ing the association between SSRIs exposure and longitudinal blood pressure measures. The
proposed model framework can be readily applied to other medication groups to determine
whether medication use is associated with longitudinally measured health outcomes.
Second, in Chapter 3, we extended the flexible WCE model proposed by Sylvestre and
Abrahamowicz (2009) for single exposure to compare multiple exposures. The use of flexible
weight functions using spline bases not only offered flexibility in summarizing cumulative
exposures, but also provided information on how the risk of adverse event was impacted by
the timing of the exposures. Furthermore, parameter estimation for the proposed model
can be implemented using standard statistical packages for survival analysis with time-
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dependent covariates making the proposed models applicable to many data applications.
Our simulation studies demonstrated adequate performance of the proposed methods in
parameter estimation as well as hypothesis testing using fixed number of knots. However,
simulation results also revealed inflated Type I error rates when the test was conditional
on AIC criteria selected number of knots. Further research is needed to determine a more
appropriate distribution for the LRT statistics when using a model selection criteria to
determine the number of knots.
Last, in Chapter 4, we propose a penalized Cox proportional hazards (PH) model with
functional covariates and interaction term, which can be used to examine the effect of
time-varying exposures and their interaction effect on survival outcome. Flexible weighted
cumulative exposure (WCE) model proposed by Sylvestre and Abrahamowicz (2009) and
penalized scalar-on-functions regression model by Fuchs et al. (2015) gave insight into our
model. Penalized Cox PH model discussed by Perperoglou (2014) and Gray (1992) provided
methods of parameter estimation. Furthermore, parameter estimation can be implemented
using standard statistical packages for survival analysis with time-dependent covariates
making the proposed models applicable to many data applications (Therneau et al., 2003).
Adequate performance of the proposed methods in both parameter estimation and hypoth-
esis testing was demonstrated through simulation studies. The application of the proposed
method in a cohort of depressed patients showed that there is non interaction between two
classes of antidepressants on CAD events. The proposed model framework can be applied
to other types of medication groups to examine the existence of interaction effects among
medication groups as well as the effects of medication exposures.
In conclusion, with the availability of Electronic medical records (EMR), enormous quan-
tities of clinical data, including medical diagnosis, laboratory testing, medication dispensing
information, can be easily accessed by researchers and have been increasingly used in many
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health systems around the country, which offers an unprecedented research opportunity
for monitoring disease development, progression and treatment. In particular, medication
dispensing data allow researchers to explore complex relationships among long-term medi-
cation use, disease progression and potential side-effects in large patient populations. Our
flexible models can deal with medication exposures in several situations. More importantly,
Our models not only provide novel solutions to solve problems in medical area, but also can
be applied to many other fields when time-varying exposures are presented.
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